{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T15:29:28Z","timestamp":1794756568668,"version":"4.9.1"},"reference-count":262,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ganpo Promising Talents Supporting Plan: Talent Development Project of Leading Academic and Technological Researchers in Key Disciplines","award":["20243BCE51060"],"award-info":[{"award-number":["20243BCE51060"]}]},{"name":"the Jiangxi Provincial Natural Science Foundation","award":["20242BAB25521"],"award-info":[{"award-number":["20242BAB25521"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473256"],"award-info":[{"award-number":["82473256"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Anhui Provincial Training Program for Young and Middle-aged University Teachers","award":["JWFX2025005"],"award-info":[{"award-number":["JWFX2025005"]}]},{"name":"the Anhui Provincial Natural Science Foundation","award":["2508085Y050"],"award-info":[{"award-number":["2508085Y050"]}]},{"name":"the Health Research Program of Anhui","award":["AHWJ2024Aa30066"],"award-info":[{"award-number":["AHWJ2024Aa30066"]}]},{"name":"the Anhui Provincial Quality Engineering Project for Higher Education","award":["2023jyxm1106"],"award-info":[{"award-number":["2023jyxm1106"]}]},{"name":"the Postgraduate Scientific Research and Practice Innovation Project of Anhui Medical University","award":["YJS20240087"],"award-info":[{"award-number":["YJS20240087"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multidrug resistance (MDR) remains the core clinical barrier limiting the achievement of durable and effective treatment for various tumors. With the deepening of understanding, MDR has been redefined from the traditional, static \u201cdrug efflux\u201d model to a systemically adaptive survival strategy driven by highly heterogeneous tumor populations under therapeutic pressure, characterized by dynamic evolution. This complex phenotype arises from the deep intertwining and synergistic action of multi-layered survival networks. Herein, this review systematically delineates the evolution and multidimensional remodeling of the underlying mechanisms of MDR. We comprehensively outline the cell-intrinsic, autonomous resistance mechanisms of tumor cells, including intracellular drug redistribution and evasion of non-apoptotic cell death pathways. Concurrently, we summarize the tumor microenvironment (TME)-mediated, non-autonomous resistance mechanisms, such as physical barriers formed by stromal cells, intercellular communication networks, and the establishment of a profoundly immunosuppressive microenvironment. Building on this foundation, the review critically assesses the current drug resistance dilemmas faced by various therapeutic modalities and refractory cancer types. It focuses on discussing novel, precision reversal strategies targeting MDR, including nanotechnology-based delivery systems, single-cell and spatial omics analysis, and artificial intelligence (AI) large model-driven predictive and interventional systems. Furthermore, this review explores the underlying reasons for the repeated clinical failures of traditional single-target interventions. It outlines a direction for future translational research: a paradigm shift from \u201csingular target killing\u201d to \u201cmultidimensional ecological remodeling,\u201d advancing towards a closed-loop, personalized precision therapy framework based on dynamic monitoring and multi-target synergistic intervention.<\/jats:p>","DOI":"10.1186\/s43556-026-00502-8","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:06:20Z","timestamp":1782443180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Multidrug resistance in cancer: current understandings and future perspective"],"prefix":"10.1186","volume":"7","author":[{"given":"Yang","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyu","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyue","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0685-4766","authenticated-orcid":false,"given":"Xingliang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"502_CR1","doi-asserted-by":"publisher","first-page":"101310","DOI":"10.1016\/j.drup.2025.101310","volume":"84","author":"D Sun","year":"2026","unstructured":"Sun D, Bo L, Jiang C, Lan Y, Zhang B, Zhang C, et al. Beyond the boundary: the emerging roles of ATP-binding cassette transporters in multidrug resistance (MDR) and therapeutic targeting in cancer. Drug Resist Updat. 2026;84:101310. https:\/\/doi.org\/10.1016\/j.drup.2025.101310.","journal-title":"Drug Resist Updat"},{"key":"502_CR2","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41571-025-01059-1","volume":"22","author":"M Ge","year":"2025","unstructured":"Ge M, Chen X-Y, Huang P, Fleishman JS, Yang D-H, Wu Z-X, et al. Understanding and overcoming multidrug resistance in cancer. Nat Rev Clin Oncol. 2025;22:760\u201380. https:\/\/doi.org\/10.1038\/s41571-025-01059-1.","journal-title":"Nat Rev Clin Oncol"},{"key":"502_CR3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ccell.2024.01.012","volume":"42","author":"X Tong","year":"2024","unstructured":"Tong X, Patel AS, Kim E, Li H, Chen Y, Li S, et al. Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer. Cancer Cell. 2024;42:413-428.e7. https:\/\/doi.org\/10.1016\/j.ccell.2024.01.012.","journal-title":"Cancer Cell"},{"key":"502_CR4","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1038\/s41556-025-01810-x","volume":"27","author":"AF Williams","year":"2025","unstructured":"Williams AF, Gervasio DAG, Turkal CE, Stuhlfire AE, Wang MX, Mauch BE, et al. DNA fragmentation factor B suppresses interferon to enable cancer persister cell regrowth. Nat Cell Biol. 2025;27:2143\u201351. https:\/\/doi.org\/10.1038\/s41556-025-01810-x.","journal-title":"Nat Cell Biol"},{"key":"502_CR5","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1158\/0008-5472.CAN-25-0999","volume":"85","author":"EA Oliveira","year":"2025","unstructured":"Oliveira EA, Milite S, Fernandez-Mateos J, Cresswell GD, Yara-Romero E, Vlachogiannis G, et al. Epigenetic heritability of cell plasticity drives cancer drug resistance through a one-to-many genotype-to-phenotype paradigm. Cancer Res. 2025;85:2921\u201338. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-0999.","journal-title":"Cancer Res"},{"issue":"1","key":"502_CR6","doi-asserted-by":"publisher","first-page":"48100","DOI":"10.1038\/s41467-024-48100-y","volume":"15","author":"B Guan","year":"2024","unstructured":"Guan B, Liu Y, Xie B, Zhao S, Yalikun A, Chen W, et al. Mitochondrial genome transfer drives metabolic reprogramming in adjacent colonic epithelial cells promoting TGF\u03b21-mediated tumor progression. Nat Commun. 2024;15(1):48100. https:\/\/doi.org\/10.1038\/s41467-024-48100-y.","journal-title":"Nat Commun"},{"key":"502_CR7","doi-asserted-by":"publisher","first-page":"37815","DOI":"10.1021\/acsnano.5c10776","volume":"19","author":"S Chang","year":"2025","unstructured":"Chang S, Chen Q, Guan G, Zhao M, Ding G, Yuan Y, et al. In Situ remodeling of tumor microenvironment via specific cancer-associated fibroblasts subtype engineering to boost antitumor immunity. ACS Nano. 2025;19:37815\u201336. https:\/\/doi.org\/10.1021\/acsnano.5c10776.","journal-title":"ACS Nano"},{"key":"502_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41568-025-00879-8","volume":"26","author":"C Mao","year":"2025","unstructured":"Mao C, Jiang D, Koong AC, Gan B. Exploiting metabolic cell death for cancer therapy. Nat Rev Cancer. 2025;26:27\u201345. https:\/\/doi.org\/10.1038\/s41568-025-00879-8.","journal-title":"Nat Rev Cancer"},{"key":"502_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.actbio.2022.04.050","volume":"146","author":"W Wu","year":"2022","unstructured":"Wu W, Li X, Yu S. Patient-derived tumour organoids: a bridge between cancer biology and personalised therapy. Acta Biomater. 2022;146:23\u201336. https:\/\/doi.org\/10.1016\/j.actbio.2022.04.050.","journal-title":"Acta Biomater"},{"issue":"12","key":"502_CR10","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s41589-024-01803-1","volume":"21","author":"B Cheng","year":"2025","unstructured":"Cheng B, Li M, Zheng J, Liang J, Li Y, Liang R, et al. Chemically engineered antibodies for autophagy-based receptor degradation. Nat Chem Biol. 2025;21(12):1452\u201360. https:\/\/doi.org\/10.1038\/s41589-024-01803-1.","journal-title":"Nat Chem Biol"},{"key":"502_CR11","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41568-023-00612-3","volume":"23","author":"A Sajid","year":"2023","unstructured":"Sajid A, Rahman H, Ambudkar SV. Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters. Nat Rev Cancer. 2023;23:762\u201379. https:\/\/doi.org\/10.1038\/s41568-023-00612-3.","journal-title":"Nat Rev Cancer"},{"key":"502_CR12","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41586-024-07690-9","volume":"631","author":"GS Franca","year":"2024","unstructured":"Franca GS, Baron M, King BR, Bossowski JP, Bjornberg A, Pour M, et al. Cellular adaptation to cancer therapy along a resistance continuum. Nature. 2024;631:876\u201383. https:\/\/doi.org\/10.1038\/s41586-024-07690-9.","journal-title":"Nature"},{"issue":"1","key":"502_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-024-01545-6","volume":"17","author":"S Zhou","year":"2024","unstructured":"Zhou S, Liu J, Wan A, Zhang Y, Qi X. Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis. J Hematol Oncol. 2024;17(1):22. https:\/\/doi.org\/10.1186\/s13045-024-01545-6.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"502_CR14","doi-asserted-by":"publisher","first-page":"023010","DOI":"10.1103\/prxlife.2.023010","volume":"2","author":"J Maltas","year":"2024","unstructured":"Maltas J, Tadele DS, Durmaz A, McFarland CD, Hinczewski M, Scott JG. Frequency-dependent ecological interactions increase the prevalence, and shape the distribution, of preexisting drug resistance. PRX Life. 2024;2(2):023010. https:\/\/doi.org\/10.1103\/prxlife.2.023010.","journal-title":"PRX Life"},{"key":"502_CR15","doi-asserted-by":"publisher","first-page":"101355","DOI":"10.1016\/j.drup.2026.101355","volume":"85","author":"M Tufail","year":"2026","unstructured":"Tufail M, Gong K, Ijaz B, Patel H, Lui W-O, Wang X, et al. The hallmarks of oncogenic signaling: from pathways to resistance in cancer therapy. Drug Resist Updat. 2026;85:101355. https:\/\/doi.org\/10.1016\/j.drup.2026.101355.","journal-title":"Drug Resist Updat"},{"key":"502_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41568-025-00824-9","volume":"25","author":"A Soragni","year":"2025","unstructured":"Soragni A, Knudsen ES, O\u2019Connor TN, Tognon CE, Tyner JW, Gini B, et al. Acquired resistance in cancer: towards targeted therapeutic strategies. Nat Rev Cancer. 2025;25:613\u201333. https:\/\/doi.org\/10.1038\/s41568-025-00824-9.","journal-title":"Nat Rev Cancer"},{"key":"502_CR17","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1158\/2159-8290.CD-23-0656","volume":"14","author":"SP Choudhuri","year":"2024","unstructured":"Choudhuri SP, Girard L, Lim JYS, Wise JF, Freitas B, Yang D, et al. Acquired cross-resistance in small cell lung cancer due to extrachromosomal DNA Amplification of MYC paralogs. Cancer Discov. 2024;14:804\u201327. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0656.","journal-title":"Cancer Discov"},{"issue":"1","key":"502_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12943-025-02493-6","volume":"24","author":"R Ibusuki","year":"2025","unstructured":"Ibusuki R, Iwama E, Shimauchi A, Kawano H, Mizusaki S, Nakamura S, et al. IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non\u2013small cell lung cancer. Mol Cancer. 2025;24(1):15. https:\/\/doi.org\/10.1186\/s12943-025-02493-6.","journal-title":"Mol Cancer"},{"key":"502_CR19","doi-asserted-by":"publisher","first-page":"108488","DOI":"10.1016\/j.pharmthera.2023.108488","volume":"249","author":"J Dong","year":"2023","unstructured":"Dong J, Yuan L, Hu C, Cheng X, Qin J-J. Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review. Pharmacol Ther. 2023;249:108488. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108488.","journal-title":"Pharmacol Ther"},{"key":"502_CR20","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.3390\/ijms26104701","volume":"26","author":"P \u00c1lvarez-Carrasco","year":"2025","unstructured":"\u00c1lvarez-Carrasco P, Morales-Villamil F, Maldonado-Bernal C. P-Glycoprotein as a therapeutic target in hematological malignancies: a challenge to overcome. Int J Mol Sci. 2025;26:4701. https:\/\/doi.org\/10.3390\/ijms26104701.","journal-title":"Int J Mol Sci"},{"key":"502_CR21","doi-asserted-by":"publisher","first-page":"10403","DOI":"10.1038\/s41467-025-65318-6","volume":"16","author":"Q Tang","year":"2025","unstructured":"Tang Q, Sinclair M, Bisignano P, Zhang Y, Tajkhorshid E, Mchaourab HS. Drug-bound outward-facing conformation of a heterodimeric ABC exporter suggests a putative mechanism of drug translocation. Nat Commun. 2025;16:10403. https:\/\/doi.org\/10.1038\/s41467-025-65318-6.","journal-title":"Nat Commun"},{"key":"502_CR22","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature22345","volume":"546","author":"NMI Taylor","year":"2017","unstructured":"Taylor NMI, Manolaridis I, Jackson SM, Kowal J, Stahlberg H, Locher KP. Structure of the human multidrug transporter ABCG2. Nature. 2017;546:504\u20139. https:\/\/doi.org\/10.1038\/nature22345.","journal-title":"Nature"},{"key":"502_CR23","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.3390\/ijms25063116","volume":"25","author":"M Ragu\u017e","year":"2024","unstructured":"Ragu\u017e M, Tarle M, M\u00fcller D, Tomasovi\u0107-Lon\u010dari\u0107 \u010c, Chudy H, Marinovi\u0107 T, et al. ABCG2 expression as a potential survival predictor in human gliomas. Int J Mol Sci. 2024;25:3116. https:\/\/doi.org\/10.3390\/ijms25063116.","journal-title":"Int J Mol Sci"},{"key":"502_CR24","doi-asserted-by":"publisher","first-page":"218254","DOI":"10.1016\/j.canlet.2026.218254","volume":"640","author":"I Prantl","year":"2026","unstructured":"Prantl I, Grausenburger R, M\u00fcller J, Baumfried O, Ertl IE, N\u00f6ssing C, et al. ABCG2-mediated SN-38 efflux drives resistance to sacituzumab govitecan in urothelial carcinoma. Cancer Lett. 2026;640:218254. https:\/\/doi.org\/10.1016\/j.canlet.2026.218254.","journal-title":"Cancer Lett"},{"key":"502_CR25","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.3390\/biomedicines12102394","volume":"12","author":"A Jele\u0144","year":"2024","unstructured":"Jele\u0144 A, \u017bebrowska-Nawrocka M, \u0141ochowski M, Szmajda-Krygier D, Balcerczak E. ABCG2 gene expression in non-small cell lung cancer. Biomedicines. 2024;12:2394. https:\/\/doi.org\/10.3390\/biomedicines12102394.","journal-title":"Biomedicines"},{"key":"502_CR26","doi-asserted-by":"publisher","first-page":"10539","DOI":"10.3390\/ijms241310539","volume":"24","author":"A Sa\u0142agacka-Kubiak","year":"2023","unstructured":"Sa\u0142agacka-Kubiak A, Zawada D, Saed L, Kordek R, Jele\u0144 A, Balcerczak E. ABCG2 gene and ABCG2 protein expression in colorectal cancer\u2014in silico and wet analysis. Int J Mol Sci. 2023;24:10539. https:\/\/doi.org\/10.3390\/ijms241310539.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"502_CR27","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1038\/s41467-025-58378-1","volume":"16","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Zhang X, Liu K, Zhu Y, Nie X, Ma J, et al. Molecular basis of SLC19A1-mediated folate and cyclic dinucleotide transport. Nat Commun. 2025;16(1):4832. https:\/\/doi.org\/10.1038\/s41467-025-58378-1.","journal-title":"Nat Commun"},{"issue":"1","key":"502_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41698-025-01198-9","volume":"10","author":"X Zhang","year":"2026","unstructured":"Zhang X, Feng J, Cai X, Xu W, Ding T, He M, et al. The regulatory roles and therapeutic strategies of the solute carrier transporters in cancer metabolism. Npj Precis Oncol. 2026;10(1):42. https:\/\/doi.org\/10.1038\/s41698-025-01198-9.","journal-title":"Npj Precis Oncol"},{"key":"502_CR29","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.3390\/pharmaceutics17101255","volume":"17","author":"P Mlejnek","year":"2025","unstructured":"Mlejnek P. Lysosomal drug sequestration mediated by abc transporters and drug resistance. Pharmaceutics. 2025;17:1255. https:\/\/doi.org\/10.3390\/pharmaceutics17101255.","journal-title":"Pharmaceutics"},{"key":"502_CR30","doi-asserted-by":"publisher","unstructured":"Dey D, Marciano S, Poryvai A, Groborz O, Wohlrabov\u00e1 L, Slanina T, et al. Reversing protonation of weakly basic drugs greatly enhances intracellular diffusion and decreases lysosomal sequestration. bioRxiv. 2023:2023.04.19.537456. https:\/\/doi.org\/10.1101\/2023.04.19.537456.","DOI":"10.1101\/2023.04.19.537456"},{"key":"502_CR31","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41419-025-07900-w","volume":"16","author":"B Sergi","year":"2025","unstructured":"Sergi B, Yuksel-Catal N, Ozcan SC, Syed H, Duvvuri U, Kiselyov K, et al. Epidrug screening identifies type I PRMT inhibitors as modulators of lysosomal exocytosis and drug sensitivity in cancers. Cell Death Dis. 2025;16:600. https:\/\/doi.org\/10.1038\/s41419-025-07900-w.","journal-title":"Cell Death Dis"},{"key":"502_CR32","doi-asserted-by":"publisher","first-page":"454","DOI":"10.7150\/ijbs.96672","volume":"21","author":"S Ganguly","year":"2025","unstructured":"Ganguly S, Burikhanov R, Sviripa VM, Ellingson S, Jiang J, Gosser CM, et al. S6K1 is a targetable vulnerability in tumors exhibiting plasticity and therapy resistance. Int J Biol Sci. 2025;21:454\u201372. https:\/\/doi.org\/10.7150\/ijbs.96672.","journal-title":"Int J Biol Sci"},{"key":"502_CR33","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/2159-8290.CD-23-0704","volume":"14","author":"A Varkaris","year":"2023","unstructured":"Varkaris A, de la Cruz FF, Martin EE, Norden BL, Chevalier N, Kehlmann AM, et al. Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations. Cancer Discov. 2023;14:227\u201339. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0704.","journal-title":"Cancer Discov"},{"issue":"8","key":"502_CR34","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1158\/1538-7445.AM2025-420","volume":"85","author":"G Picco","year":"2025","unstructured":"Picco G, Rao Y, Saedi AA, Walker SJ, Bhosle S, Lee Y, et al. Abstract 420: On-target mutations confer resistance to WRN helicase inhibitors in microsatellite unstable cancer cells. Cancer Res. 2025;85(8):420. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-420.","journal-title":"Cancer Res"},{"issue":"11","key":"502_CR35","doi-asserted-by":"publisher","first-page":"102253","DOI":"10.1016\/j.xcrm.2025.102253","volume":"6","author":"MS Theardy","year":"2025","unstructured":"Theardy MS, Takeda M, Sorokin A, Chen S, Yang Z, Wang X, et al. Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. Cell Rep Med. 2025;6(11):102253. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102253.","journal-title":"Cell Rep Med"},{"key":"502_CR36","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1158\/2159-8290.CD-23-0361","volume":"13","author":"A Drilon","year":"2023","unstructured":"Drilon A, Sharma MR, Johnson ML, Yap TA, Gadgeel S, Nepert D, et al. SHP2 inhibition sensitizes diverse oncogene-addicted solid tumors to re-treatment with targeted therapy. Cancer Discov. 2023;13:1789\u2013801. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0361.","journal-title":"Cancer Discov"},{"issue":"28","key":"502_CR37","doi-asserted-by":"publisher","first-page":"e2300115","DOI":"10.1002\/advs.202300115","volume":"10","author":"X Wang","year":"2023","unstructured":"Wang X, Wang B, Li F, Li X, Guo T, Gao Y, et al. The c-Src\/LIST positive feedback loop sustains tumor progression and chemoresistance. Adv Sci. 2023;10(28):e2300115. https:\/\/doi.org\/10.1002\/advs.202300115.","journal-title":"Adv Sci"},{"issue":"1","key":"502_CR38","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41392-024-01891-4","volume":"9","author":"J He","year":"2024","unstructured":"He J, Qiu Z, Fan J, Xie X, Sheng Q, Sui X, et al. Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies. Signal Transduct Target Ther. 2024;9(1):312. https:\/\/doi.org\/10.1038\/s41392-024-01891-4.","journal-title":"Signal Transduct Target Ther"},{"key":"502_CR39","doi-asserted-by":"publisher","first-page":"117880","DOI":"10.1016\/j.biopha.2025.117880","volume":"183","author":"D Keresztes","year":"2025","unstructured":"Keresztes D, Kerest\u00e9ly M, Szarka L, Kov\u00e1cs BM, Schulc K, Veres DV, et al. Cancer drug resistance as learning of signaling networks. Biomed Pharmacother. 2025;183:117880. https:\/\/doi.org\/10.1016\/j.biopha.2025.117880.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"502_CR40","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1158\/2159-8290.cd-22-0787","volume":"13","author":"P Dharanipragada","year":"2023","unstructured":"Dharanipragada P, Zhang X, Liu S, Lomeli SH, Hong A, Wang Y, et al. Blocking genomic instability prevents acquired resistance to MAPK inhibitor therapy in melanoma. Cancer Discov. 2023;13(4):880\u2013909. https:\/\/doi.org\/10.1158\/2159-8290.cd-22-0787.","journal-title":"Cancer Discov"},{"issue":"2","key":"502_CR41","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ccell.2025.06.005","volume":"43","author":"A Jassim","year":"2025","unstructured":"Jassim A, Nimmervoll BV, Terranova S, Nathan E, Hu L, Taylor JT, et al. Gene context drift identifies drug targets to mitigate cancer treatment resistance. Cancer Cell. 2025;43(2):210\u201325. https:\/\/doi.org\/10.1016\/j.ccell.2025.06.005.","journal-title":"Cancer Cell"},{"key":"502_CR42","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.7150\/ijbs.120657","volume":"21","author":"J Zhao","year":"2025","unstructured":"Zhao J, Zhang Y, Wei Z, Li K, Sun L, Li D, et al. The PI3K\/Akt\/mTOR pathway: immuno-metabolic orchestration in IR\/MASH-associated hepatocellular carcinoma. Int J Biol Sci. 2025;21:6025\u201341. https:\/\/doi.org\/10.7150\/ijbs.120657.","journal-title":"Int J Biol Sci"},{"key":"502_CR43","doi-asserted-by":"publisher","first-page":"101315","DOI":"10.1016\/j.drup.2025.101315","volume":"84","author":"H Zhang","year":"2026","unstructured":"Zhang H, Sun Y, Liu R, Hamdy H, Shi Z, Jiang D, et al. The role of tumor microenvironment and signaling pathways in regulating breast cancer stem cells: implications for therapy resistance and tumor recurrence. Drug Resist Updat. 2026;84:101315. https:\/\/doi.org\/10.1016\/j.drup.2025.101315.","journal-title":"Drug Resist Updat"},{"issue":"812","key":"502_CR44","doi-asserted-by":"publisher","first-page":"eadp5088","DOI":"10.1126\/scitranslmed.adp5088","volume":"17","author":"CL Alves","year":"2025","unstructured":"Alves CL, Karimi L, Terp MG, Jakobsen MK, Zhou FH, Policastro B, et al. Dual PI3K\/mTOR inhibition is required to combat resistance to CDK4\/6 inhibitor and endocrine therapy in PIK3CA-mutant breast cancer. Sci Transl Med. 2025;17(812):eadp5088. https:\/\/doi.org\/10.1126\/scitranslmed.adp5088.","journal-title":"Sci Transl Med"},{"issue":"1","key":"502_CR45","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1186\/s12964-024-01941-y","volume":"22","author":"J Delyon","year":"2024","unstructured":"Delyon J, Becherirat S, Roger A, Bernard-Cacciarella M, Moura CRD, Louveau B, et al. PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors. Cell Commun Signal. 2024;22(1):584. https:\/\/doi.org\/10.1186\/s12964-024-01941-y.","journal-title":"Cell Commun Signal"},{"key":"502_CR46","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1038\/s44319-025-00521-6","volume":"26","author":"J Yu","year":"2025","unstructured":"Yu J, He X, Wang X, Yu C, Jiang X, Li Y, et al. Transcriptome-wide decoding the roles of aberrant splicing in melanoma MAPK-targeted resistance evolution. EMBO Rep. 2025;26:4180\u201396. https:\/\/doi.org\/10.1038\/s44319-025-00521-6.","journal-title":"EMBO Rep"},{"key":"502_CR47","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41586-025-09916-w","volume":"650","author":"M White","year":"2025","unstructured":"White M, Mills ML, Millett LM, Gilroy K, Hong Y, Zeiger LB, et al. MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance. Nature. 2025;650:748\u201358. https:\/\/doi.org\/10.1038\/s41586-025-09916-w.","journal-title":"Nature"},{"key":"502_CR48","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/0008-5472.CAN-22-0423","volume":"83","author":"LE Stevens","year":"2022","unstructured":"Stevens LE, Peluffo G, Qiu X, Temko D, Fassl A, Li Z, et al. JAK\u2013STAT signaling in inflammatory breast cancer enables chemotherapy-resistant cell states. Cancer Res. 2022;83:264\u201384. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-0423.","journal-title":"Cancer Res"},{"issue":"1","key":"502_CR49","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41698-025-00947-0","volume":"9","author":"EPB Rodman","year":"2025","unstructured":"Rodman EPB, Emch MJ, Hou X, Bajaj A, Pearson NA, John AJ, et al. Lestaurtinib\u2019s antineoplastic activity converges on JAK\/STAT signaling to inhibit treatment naive and therapy resistant forms ovarian cancer. npj Precis Oncol. 2025;9(1):92. https:\/\/doi.org\/10.1038\/s41698-025-00947-0.","journal-title":"npj Precis Oncol"},{"key":"502_CR50","doi-asserted-by":"publisher","first-page":"101042","DOI":"10.1016\/j.drup.2023.101042","volume":"73","author":"Y Li","year":"2024","unstructured":"Li Y, Zhao B, Peng J, Tang H, Wang S, Peng S, et al. Inhibition of NF-\u03baB signaling unveils novel strategies to overcome drug resistance in cancers. Drug Resist Updat. 2024;73:101042. https:\/\/doi.org\/10.1016\/j.drup.2023.101042.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"502_CR51","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41419-025-07900-w","volume":"16","author":"A Vareli","year":"2025","unstructured":"Vareli A, Vaidehi Narayanan H, Clark H, Jayawant E, Zhou H, Liu Y, et al. Epidrug screening identifies type I PRMT inhibitors as modulators of lysosomal exocytosis and drug sensitivity in cancers. Cell Death Dis. 2025;16(1):600. https:\/\/doi.org\/10.1038\/s41419-025-07900-w.","journal-title":"Cell Death Dis"},{"key":"502_CR52","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.7150\/ijbs.84781","volume":"19","author":"P-C Jiang","year":"2023","unstructured":"Jiang P-C, Fan J, Zhang C-D, Bai M-H, Sun Q-Q, Chen Q-P, et al. Unraveling colorectal cancer and pan-cancer immune heterogeneity and synthetic therapy response using cuproptosis and hypoxia regulators by multi-omic analysis and experimental validation. Int J Biol Sci. 2023;19:3526\u201343. https:\/\/doi.org\/10.7150\/ijbs.84781.","journal-title":"Int J Biol Sci"},{"issue":"7999","key":"502_CR53","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41586-023-06983-9","volume":"626","author":"Y Li","year":"2024","unstructured":"Li Y, Ran Q, Duan Q, Jin J, Wang Y, Yu L, et al. 7-Dehydrocholesterol dictates ferroptosis sensitivity. Nature. 2024;626(7999):411\u20138. https:\/\/doi.org\/10.1038\/s41586-023-06983-9.","journal-title":"Nature"},{"key":"502_CR54","doi-asserted-by":"publisher","first-page":"101351","DOI":"10.1016\/j.drup.2026.101351","volume":"85","author":"L Ni","year":"2026","unstructured":"Ni L, Li H, Chen P, Yu Y, Xie C, Hong W, et al. Linc01833 drives gemcitabine resistance in non-small cell lung cancer by shielding SLC7A11 from WWP1-mediated ubiquitination and inhibiting ferroptosis. Drug Resist Updat. 2026;85:101351. https:\/\/doi.org\/10.1016\/j.drup.2026.101351.","journal-title":"Drug Resist Updat"},{"key":"502_CR55","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1016\/j.molcel.2025.11.023","volume":"85","author":"Y Hu","year":"2025","unstructured":"Hu Y, Li Z, Li M, Wu X, Zhang S, Tang M, et al. Targeting PRDX6-dependent localization and function of GPX4 enhances ferroptosis-mediated tumor suppression. Mol Cell. 2025;85:4602-4620.e9. https:\/\/doi.org\/10.1016\/j.molcel.2025.11.023.","journal-title":"Mol Cell"},{"issue":"1","key":"502_CR56","doi-asserted-by":"publisher","first-page":"10324","DOI":"10.1038\/s41467-023-44412-7","volume":"15","author":"H Lee","year":"2024","unstructured":"Lee H, Horbath A, Kondipartihi L, Meena JK, Lei G, Dasgupta S, et al. Cell cycle arrest induces lipid droplet formation and confers ferroptosis resistance. Nat Commun. 2024;15(1):10324. https:\/\/doi.org\/10.1038\/s41467-023-44412-7.","journal-title":"Nat Commun"},{"key":"502_CR57","doi-asserted-by":"publisher","unstructured":"Zhang H-L, Hu B-X, Ye Z-P, Li Z-L, Liu S, Zhong W-Q, et al. TRPML1 triggers ferroptosis defense and is a potential therapeutic target in AKT-hyperactivated cancer. Sci Transl Med. 2024;16(756):eadk0330. https:\/\/doi.org\/10.1126\/scitranslmed.adk0330.","DOI":"10.1126\/scitranslmed.adk0330"},{"key":"502_CR58","doi-asserted-by":"publisher","first-page":"103826","DOI":"10.1016\/j.redox.2025.103826","volume":"86","author":"N Zheng","year":"2025","unstructured":"Zheng N, Li F, Huang Q, Huang X, Maj T. Macrophages and macrophage extracellular vesicles confer cancer ferroptosis resistance via PRDX6-mediated mitophagy inhibition. Redox Biol. 2025;86:103826. https:\/\/doi.org\/10.1016\/j.redox.2025.103826.","journal-title":"Redox Biol"},{"issue":"3","key":"502_CR59","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41556-026-01907-x","volume":"28","author":"Y-Y Zhang","year":"2026","unstructured":"Zhang Y-Y, Han Y, Tan Y-T, Lu Y-X, Ma M-Y, Zheng Y-Q, et al. Peritumoural adipose tissue promotes ferroptosis resistance by 3-hydroxykynurenine-mediated suppression of ferritinophagy. Nat Cell Biol. 2026;28(3):321\u201333. https:\/\/doi.org\/10.1038\/s41556-026-01907-x.","journal-title":"Nat Cell Biol"},{"key":"502_CR60","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12943-023-01732-y","volume":"22","author":"J Xie","year":"2023","unstructured":"Xie J, Yang Y, Gao Y, He J. Cuproptosis: mechanisms and links with cancers. Mol Cancer. 2023;22:46. https:\/\/doi.org\/10.1186\/s12943-023-01732-y.","journal-title":"Mol Cancer"},{"issue":"5","key":"502_CR61","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.ccell.2025.02.015","volume":"43","author":"Z Yang","year":"2025","unstructured":"Yang Z, Su W, Wei X, Pan Y, Xing M, Niu L, et al. Hypoxia inducible factor-1\u03b1 drives cancer resistance to cuproptosis. Cancer Cell. 2025;43(5):937-954.e9. https:\/\/doi.org\/10.1016\/j.ccell.2025.02.015.","journal-title":"Cancer Cell"},{"issue":"32","key":"502_CR62","doi-asserted-by":"publisher","first-page":"e2408106","DOI":"10.1002\/advs.202408106","volume":"12","author":"Z Sun","year":"2025","unstructured":"Sun Z, Xu H, Lu G, Yang C, Gao X, Zhang J, et al. AKT1 phosphorylates FDX1 to promote cuproptosis resistance in triple-negative breast cancer. Adv Sci. 2025;12(32):e2408106. https:\/\/doi.org\/10.1002\/advs.202408106.","journal-title":"Adv Sci"},{"issue":"26","key":"502_CR63","doi-asserted-by":"publisher","first-page":"7248","DOI":"10.1016\/j.cell.2024.09.032","volume":"187","author":"L Xu","year":"2024","unstructured":"Xu L, Peng F, Luo Q, Ding Y, Yuan F, Zheng L, et al. IRE1\u03b1 silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer. Cell. 2024;187(26):7248-7266.e34. https:\/\/doi.org\/10.1016\/j.cell.2024.09.032.","journal-title":"Cell"},{"issue":"4","key":"502_CR64","doi-asserted-by":"publisher","first-page":"e13644","DOI":"10.1111\/cpr.13644","volume":"57","author":"L Yu","year":"2024","unstructured":"Yu L, Huang K, Liao Y, Wang L, Sethi G, Ma Z. Targeting novel regulated cell death: Ferroptosis, pyroptosis and necroptosis in anti-PD-1\/PD-L1 cancer immunotherapy. Cell Prolif. 2024;57(4):e13644. https:\/\/doi.org\/10.1111\/cpr.13644.","journal-title":"Cell Prolif"},{"key":"502_CR65","doi-asserted-by":"publisher","first-page":"101097","DOI":"10.1016\/j.drup.2024.101097","volume":"76","author":"J Lin","year":"2024","unstructured":"Lin J, Lyu Z, Feng H, Xie H, Peng J, Zhang W, et al. CircPDIA3\/miR-449a\/XBP1 feedback loop curbs pyroptosis by inhibiting palmitoylation of the GSDME-C domain to induce chemoresistance of colorectal cancer. Drug Resist Updat. 2024;76:101097. https:\/\/doi.org\/10.1016\/j.drup.2024.101097.","journal-title":"Drug Resist Updat"},{"issue":"11","key":"502_CR66","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41556-025-01740-8","volume":"27","author":"N Yang","year":"2025","unstructured":"Yang N, Li X, Huang W, Ji G, Luo W, Jiang F, et al. MLKL PARylation in the endothelial niche triggers angiocrine necroptosis to evade cancer immunosurveillance and chemotherapy. Nat Cell Biol. 2025;27(11):1742\u201354. https:\/\/doi.org\/10.1038\/s41556-025-01740-8.","journal-title":"Nat Cell Biol"},{"issue":"8003","key":"502_CR67","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-024-07103-x","volume":"627","author":"M Yamagishi","year":"2024","unstructured":"Yamagishi M, Kuze Y, Kobayashi S, Nakashima M, Morishima S, Kawamata T, et al. Mechanisms of action and resistance in histone methylation-targeted therapy. Nature. 2024;627(8003):221\u20138. https:\/\/doi.org\/10.1038\/s41586-024-07103-x.","journal-title":"Nature"},{"issue":"13","key":"502_CR68","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1016\/j.cell.2024.04.025","volume":"187","author":"MB Maxwell","year":"2024","unstructured":"Maxwell MB, Hom-Tedla MS, Yi J, Li S, Rivera SA, Yu J, et al. ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity. Cell. 2024;187(13):3390-3408.e19. https:\/\/doi.org\/10.1016\/j.cell.2024.04.025.","journal-title":"Cell"},{"issue":"10","key":"502_CR69","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1038\/s41556-024-01473-0","volume":"26","author":"G Lv","year":"2024","unstructured":"Lv G, Wang Q, Lin L, Ye Q, Li X, Zhou Q, et al. mTORC2-driven chromatin cGAS mediates chemoresistance through epigenetic reprogramming in colorectal cancer. Nat Cell Biol. 2024;26(10):1585\u201396. https:\/\/doi.org\/10.1038\/s41556-024-01473-0.","journal-title":"Nat Cell Biol"},{"issue":"22","key":"502_CR70","doi-asserted-by":"publisher","first-page":"e176851","DOI":"10.1172\/jci176851","volume":"134","author":"S Wang","year":"2024","unstructured":"Wang S, Huang T, Wu Q, Yuan H, Wu X, Yuan F, et al. Lactate reprograms glioblastoma immunity through CBX3-regulated histone lactylation. J Clin Invest. 2024;134(22):e176851. https:\/\/doi.org\/10.1172\/jci176851.","journal-title":"J Clin Invest"},{"issue":"42","key":"502_CR71","doi-asserted-by":"publisher","first-page":"e2509255122","DOI":"10.1073\/pnas.2509255122","volume":"122","author":"S Chen","year":"2025","unstructured":"Chen S, Zhong M, Wang X, Su Y, Zhao Y, Wang S, et al. Activation of epigenetic reprogramming via crotonylation overcomes resistance to EGFR-TKI therapy in lung cancer. Proc Natl Acad Sci U S A. 2025;122(42):e2509255122. https:\/\/doi.org\/10.1073\/pnas.2509255122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"502_CR72","doi-asserted-by":"publisher","first-page":"e186467","DOI":"10.1172\/jci186467","volume":"135","author":"AJ Duval","year":"2025","unstructured":"Duval AJ, Seker-Polat F, Rogozinska M, Kinali M, Walts AE, Neyisci O, et al. SOX9 drives a stem-like transcriptional state and platinum resistance in high-grade serous ovarian cancer. J Clin Invest. 2025;135(18):e186467. https:\/\/doi.org\/10.1172\/jci186467.","journal-title":"J Clin Invest"},{"issue":"5","key":"502_CR73","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1158\/2159-8290.cd-23-0110","volume":"14","author":"Y Kazansky","year":"2024","unstructured":"Kazansky Y, Cameron D, Mueller HS, Demarest P, Zaffaroni N, Arrighetti N, et al. Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy. Cancer Discov. 2024;14(5):965\u201381. https:\/\/doi.org\/10.1158\/2159-8290.cd-23-0110.","journal-title":"Cancer Discov"},{"issue":"1","key":"502_CR74","doi-asserted-by":"publisher","first-page":"10387","DOI":"10.1038\/s41467-024-53874-2","volume":"15","author":"SS Chatterjee","year":"2024","unstructured":"Chatterjee SS, Linares JF, Cid-Diaz T, Dur\u00e1n A, Khan MIK, Osrodek M, et al. Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer. Nat Commun. 2024;15(1):10387. https:\/\/doi.org\/10.1038\/s41467-024-53874-2.","journal-title":"Nat Commun"},{"issue":"1","key":"502_CR75","doi-asserted-by":"publisher","first-page":"10892","DOI":"10.1038\/s41467-025-66376-6","volume":"16","author":"Z Wang","year":"2025","unstructured":"Wang Z, Wang M, Dong B, Wang Y, Ding Z, Shen S. Drug-tolerant persister cells in cancer: bridging the gaps between bench and bedside. Nat Commun. 2025;16(1):10892. https:\/\/doi.org\/10.1038\/s41467-025-66376-6.","journal-title":"Nat Commun"},{"issue":"1","key":"502_CR76","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41392-025-02360-2","volume":"10","author":"H Lee","year":"2025","unstructured":"Lee H, Kim B, Park J, Park S, Yoo G, Yum S, et al. Cancer stem cells: landscape, challenges and emerging therapeutic innovations. Signal Transduct Target Ther. 2025;10(1):285. https:\/\/doi.org\/10.1038\/s41392-025-02360-2.","journal-title":"Signal Transduct Target Ther"},{"key":"502_CR77","doi-asserted-by":"publisher","unstructured":"Ramponi V, Richart L, Kovatcheva M, Attolini CS-O, Capellades J, Lord AE, et al. H4K20me3-mediated repression of inflammatory genes is a characteristic and targetable vulnerability of persister cancer cells. Cancer Res. 2024;85(1):32\u201351. https:\/\/doi.org\/10.1158\/0008-5472.can-24-0529.","DOI":"10.1158\/0008-5472.can-24-0529"},{"key":"502_CR78","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141:69\u201380. https:\/\/doi.org\/10.1016\/j.cell.2010.02.027.","journal-title":"Cell"},{"issue":"5","key":"502_CR79","doi-asserted-by":"publisher","first-page":"e192599","DOI":"10.1172\/jci192599","volume":"136","author":"F Yuan","year":"2026","unstructured":"Yuan F, Wu X, Yuan H, Wang D, Huang T, Zhang P, et al. Glioblastoma stem cells resist cuproptosis with circadian variation of copper levels. J Clin Invest. 2026;136(5):e192599. https:\/\/doi.org\/10.1172\/jci192599.","journal-title":"J Clin Invest"},{"issue":"1","key":"502_CR80","doi-asserted-by":"publisher","first-page":"10988","DOI":"10.1038\/s41467-025-65888-5","volume":"16","author":"GL Joun","year":"2025","unstructured":"Joun GL, Kempe EG, Chen B, Sterling JR, Abbassi RH, Friess D, et al. Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma. Nat Commun. 2025;16(1):10988. https:\/\/doi.org\/10.1038\/s41467-025-65888-5.","journal-title":"Nat Commun"},{"key":"502_CR81","doi-asserted-by":"publisher","unstructured":"Liu S, Jiang A, Tang F, Duan M, Li B. Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment. Mol Cancer. 2025;24(1):312. https:\/\/doi.org\/10.1186\/s12943-025-02323-9.","DOI":"10.1186\/s12943-025-02323-9"},{"issue":"1","key":"502_CR82","doi-asserted-by":"publisher","first-page":"10234","DOI":"10.1038\/s41467-024-47423-0","volume":"15","author":"F Haderk","year":"2024","unstructured":"Haderk F, Chou Y-T, Cech L, Fernandez-M\u00e9ndez C, Yu J, Olivas V, et al. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nat Commun. 2024;15(1):10234. https:\/\/doi.org\/10.1038\/s41467-024-47423-0.","journal-title":"Nat Commun"},{"issue":"11","key":"502_CR83","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1158\/2159-8290.cd-24-1515","volume":"15","author":"S Baldacci","year":"2025","unstructured":"Baldacci S, Brea EJ, Facchinetti F, Li Z, Ngo K, Malhotra S, et al. Eradicating drug tolerant persister cells in EGFR-mutated non-small cell lung cancer by targeting TROP2 with CAR-T cellular therapy. Cancer Discov. 2025;15(11):2235\u201350. https:\/\/doi.org\/10.1158\/2159-8290.cd-24-1515.","journal-title":"Cancer Discov"},{"issue":"2","key":"502_CR84","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1158\/0008-5472.CAN-25-3520","volume":"86","author":"W Li","year":"2026","unstructured":"Li W, Peng J, He J, Liao L, Kang D, Zhang W, et al. PKM2 Lactylation Promotes Colorectal Cancer Vasculogenic Mimicry and Bevacizumab Resistance by Facilitating FOSL1 Super-Enhancer Formation. Cancer Res. 2026;86(2):310\u201322. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-3520.","journal-title":"Cancer Res"},{"key":"502_CR85","doi-asserted-by":"publisher","first-page":"216705","DOI":"10.1016\/j.canlet.2024.216705","volume":"587","author":"C Uslu","year":"2024","unstructured":"Uslu C, Kapan E, Lyakhovich A. Cancer resistance and metastasis are maintained through oxidative phosphorylation. Cancer Lett. 2024;587:216705. https:\/\/doi.org\/10.1016\/j.canlet.2024.216705.","journal-title":"Cancer Lett"},{"issue":"6","key":"502_CR86","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.cmet.2025.01.021","volume":"37","author":"K Borb\u00e9nyi-Galambos","year":"2025","unstructured":"Borb\u00e9nyi-Galambos K, Erd\u00e9lyi K, Ditr\u00f3i T, Jur\u00e1nyi EP, Sz\u00e1nt\u00f3 N, Szatm\u00e1ri R, et al. Realigned transsulfuration drives BRAF-V600E-targeted therapy resistance in melanoma. Cell Metab. 2025;37(6):1171-1188.e9. https:\/\/doi.org\/10.1016\/j.cmet.2025.01.021.","journal-title":"Cell Metab"},{"key":"502_CR87","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41586-024-07620-9","volume":"631","author":"H Chen","year":"2024","unstructured":"Chen H, Li Y, Li H, Chen X, Fu H, Mao D, et al. NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance. Nature. 2024;631:663\u20139. https:\/\/doi.org\/10.1038\/s41586-024-07620-9.","journal-title":"Nature"},{"issue":"16","key":"502_CR88","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1158\/1078-0432.ccr-25-0112","volume":"31","author":"R Patel","year":"2025","unstructured":"Patel R, Saab K, Luo L, Ma Y, Osman RA, Williams NT, et al. Nrf2 hyperactivation as a driver of radiotherapy resistance and suppressed anti-tumor immunity in head and neck squamous cell carcinoma. Clin Cancer Res. 2025;31(16):4184\u201395. https:\/\/doi.org\/10.1158\/1078-0432.ccr-25-0112.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"502_CR89","doi-asserted-by":"publisher","first-page":"6794","DOI":"10.7150\/ijbs.115721","volume":"21","author":"W Feng","year":"2025","unstructured":"Feng W, Liu Y, Zhang Q, Hu S, Xie D, Tan P, et al. GDF15 drives glioblastoma radioresistance by inhibiting ferroptosis and remodeling the immune microenvironment. Int J Biol Sci. 2025;21(17):6794\u2013807. https:\/\/doi.org\/10.7150\/ijbs.115721.","journal-title":"Int J Biol Sci"},{"issue":"8065","key":"502_CR90","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41586-025-08756-y","volume":"641","author":"J Zhang","year":"2025","unstructured":"Zhang J, Ali MY, Chong HB, Tien P-C, Woods J, Noble C, et al. Oxidation of retromer complex controls mitochondrial translation. Nature. 2025;641(8065):1048\u201358. https:\/\/doi.org\/10.1038\/s41586-025-08756-y.","journal-title":"Nature"},{"issue":"3","key":"502_CR91","doi-asserted-by":"publisher","first-page":"e174528","DOI":"10.1172\/JCI174528","volume":"134","author":"DJ Schaer","year":"2023","unstructured":"Schaer DJ, Schulthess-Lutz N, Baselgia L, Hansen K, Buzzi RM, Humar R, et al. Hemorrhage-activated NRF2 in tumor-associated macrophages drives cancer growth, invasion, and immunotherapy resistance. J Clin Invest. 2023;134(3):e174528. https:\/\/doi.org\/10.1172\/JCI174528.","journal-title":"J Clin Invest"},{"issue":"3","key":"502_CR92","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41556-024-01349-3","volume":"26","author":"X Xu","year":"2024","unstructured":"Xu X, Yu Y, Zhang W, Ma W, He C, Qiu G, et al. SHP-1 inhibition targets leukaemia stem cells to restore immunosurveillance and enhance chemosensitivity by metabolic reprogramming. Nat Cell Biol. 2024;26(3):464\u201377. https:\/\/doi.org\/10.1038\/s41556-024-01349-3.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"502_CR93","doi-asserted-by":"publisher","first-page":"11892","DOI":"10.1038\/s41467-025-67967-z","volume":"16","author":"S Bai","year":"2025","unstructured":"Bai S, Chen M, Wang X, Lan N, Meng R, Yan Y, et al. GPR4 promotes immune exclusion in colon cancer through LOXL2-mediated extracellular matrix remodeling. Nat Commun. 2025;16(1):11892. https:\/\/doi.org\/10.1038\/s41467-025-67967-z.","journal-title":"Nat Commun"},{"issue":"5","key":"502_CR94","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.ccell.2024.03.005","volume":"42","author":"N Niu","year":"2024","unstructured":"Niu N, Shen X, Wang Z, Chen Y, Weng Y, Yu F, et al. Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer. Cancer Cell. 2024;42(5):869-884.e9. https:\/\/doi.org\/10.1016\/j.ccell.2024.03.005.","journal-title":"Cancer Cell"},{"key":"502_CR95","doi-asserted-by":"publisher","unstructured":"XZ, AA-D, XZ, DF, LY, HW, et al. Insights into the mechanisms, regulation, and therapeutic implications of extracellular matrix stiffness in cancer. Bioeng Transl Med. 2024;10(3):e10698. https:\/\/doi.org\/10.1002\/btm2.10698.","DOI":"10.1002\/btm2.10698"},{"issue":"8","key":"502_CR96","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s41563-024-01908-x","volume":"23","author":"BL LeSavage","year":"2024","unstructured":"LeSavage BL, Zhang D, Huerta-L\u00f3pez C, Gilchrist AE, Krajina BA, Karlsson K, et al. Engineered matrices reveal stiffness-mediated chemoresistance in patient-derived pancreatic cancer organoids. Nat Mater. 2024;23(8):1138\u201349. https:\/\/doi.org\/10.1038\/s41563-024-01908-x.","journal-title":"Nat Mater"},{"issue":"19","key":"502_CR97","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1158\/0008-5472.CAN-23-0025","volume":"83","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Zhou R, Cai J, Yang N, Wen Z, Zhang Z, et al. Matrix stiffness triggers lipid metabolic crosstalk between tumor and stromal cells to mediate bevacizumab resistance in colorectal cancer liver metastases. Cancer Res. 2023;83(19):3577\u201392. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0025.","journal-title":"Cancer Res"},{"issue":"12","key":"502_CR98","doi-asserted-by":"publisher","first-page":"101576","DOI":"10.1016\/j.xcrm.2024.101576","volume":"5","author":"X Chen","year":"2024","unstructured":"Chen X, Cheng G, Zhu L, Liu T, Yang X, Liu R, et al. Alarmin S100A8 imparts chemoresistance of esophageal cancer by reprogramming cancer-associated fibroblasts. Cell Rep Med. 2024;5(12):101576. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101576.","journal-title":"Cell Rep Med"},{"issue":"1","key":"502_CR99","doi-asserted-by":"publisher","first-page":"8234","DOI":"10.1038\/s41467-023-42382-4","volume":"14","author":"J Barbazan","year":"2023","unstructured":"Barbazan J, P\u00e9rez-Gonz\u00e1lez C, Gomez-Gonzalez M, Dedenon M, Richon S, Latorre E, et al. Cancer-associated fibroblasts actively compress cancer cells and modulate mechanotransduction. Nat Commun. 2023;14(1):8234. https:\/\/doi.org\/10.1038\/s41467-023-42382-4.","journal-title":"Nat Commun"},{"issue":"18","key":"502_CR100","doi-asserted-by":"publisher","first-page":"e2500019122","DOI":"10.1073\/pnas.2500019122","volume":"122","author":"M Wang","year":"2025","unstructured":"Wang M, Wang Y, Pan X, Wang B, Wang Y, Luo X, et al. Acquired resistance to immunotherapy by physical barriers with cancer cell-expressing collagens in non-small cell lung cancer. Proc Natl Acad Sci U S A. 2025;122(18):e2500019122. https:\/\/doi.org\/10.1073\/pnas.2500019122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"502_CR101","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12943-024-02106-8","volume":"23","author":"Z Lin","year":"2024","unstructured":"Lin Z, Li G, Jiang K, Li Z, Liu T, et al. Cancer therapy resistance mediated by cancer-associated fibroblast-derived extracellular vesicles: biological mechanisms to clinical significance and implications. Mol Cancer. 2024;23(1):214. https:\/\/doi.org\/10.1186\/s12943-024-02106-8.","journal-title":"Mol Cancer"},{"issue":"7","key":"502_CR102","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","volume":"14","author":"J Prakash","year":"2024","unstructured":"Prakash J, Shaked Y, et al. The Interplay between Extracellular Matrix Remodeling and Cancer Therapeutics. Cancer Discov. 2024;14(7):1375\u201388. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0002.","journal-title":"Cancer Discov"},{"issue":"28","key":"502_CR103","doi-asserted-by":"publisher","first-page":"e2506674","DOI":"10.1002\/advs.202506674","volume":"12","author":"H Sun","year":"2025","unstructured":"Sun H, Zhang T, Zhang X, Liu Y, Wang X, Wang X, et al. Exosomal CCT6A Secreted by Cancer-Associated Fibroblasts Interacts with \u03b2-Catenin to Enhance Chemoresistance and Tumorigenesis in Gastric Cancer. Adv Sci. 2025;12(28):e2506674. https:\/\/doi.org\/10.1002\/advs.202506674.","journal-title":"Adv Sci"},{"issue":"1","key":"502_CR104","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12943-024-02180-y","volume":"23","author":"X Zhou","year":"2024","unstructured":"Zhou X, Han J, Zuo A, Ba Y, Liu S, Xu H, et al. THBS2 cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K\/AKT activation in colorectal cancer. Mol Cancer. 2024;23(1):245. https:\/\/doi.org\/10.1186\/s12943-024-02180-y.","journal-title":"Mol Cancer"},{"issue":"12","key":"502_CR105","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1158\/0008-5472.CAN-25-0966","volume":"85","author":"I Hofer","year":"2025","unstructured":"Hofer I, Kieffer Y, Mencattini A, Croizer H, Mhaidly R, Descroix S, et al. An extracellular matrix-producing subset of cancer-associated fibroblasts drives chemoresistance in breast cancer via SRC activation and G0S2 upregulation. Cancer Res. 2025;85(12):2056\u201369. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-0966.","journal-title":"Cancer Res"},{"key":"502_CR106","doi-asserted-by":"publisher","first-page":"101273","DOI":"10.1016\/j.drup.2025.101273","volume":"82","author":"X Zhang","year":"2025","unstructured":"Zhang X, Wang Y, Cui W, Li D, Song J, Li Z, et al. The multifaceted contributions of cancer-associated fibroblasts to drug resistance in primary and metastatic tumors. Drug Resist Updat. 2025;82:101273. https:\/\/doi.org\/10.1016\/j.drup.2025.101273.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"502_CR107","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12943-025-02312-y","volume":"24","author":"H Umeda","year":"2025","unstructured":"Umeda H, Shigeyasu K, Takahashi T, Moriwake K, Kondo Y, Yoshida K, et al. ADAR1-high tumor-associated macrophages induce drug resistance and are therapeutic targets in colorectal cancer. Mol Cancer. 2025;24(1):112. https:\/\/doi.org\/10.1186\/s12943-025-02312-y.","journal-title":"Mol Cancer"},{"key":"502_CR108","doi-asserted-by":"publisher","unstructured":"Zhang X, Lao M, Sun K, Yang H, He L, Liu X, et al. Sphingolipid synthesis in tumor-associated macrophages confers immunotherapy resistance in hepatocellular carcinoma. Sci Adv. 2025;11(22):eadv0558. https:\/\/doi.org\/10.1126\/sciadv.adv0558.","DOI":"10.1126\/sciadv.adv0558"},{"issue":"42","key":"502_CR109","doi-asserted-by":"publisher","first-page":"e2423894122","DOI":"10.1073\/pnas.2423894122","volume":"122","author":"ML Klosowski","year":"2025","unstructured":"Klosowski ML, Cronise KE, Palmer EP, McAuliffe K, Stratton C, Sparks K, et al. Breast cancer cell coculture induces normal lung fibroblast transition to CAFs, promoting tumor cell dormancy and therapy resistance. Proc Natl Acad Sci U S A. 2025;122(42):e2423894122. https:\/\/doi.org\/10.1073\/pnas.2423894122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"502_CR110","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.immuni.2024.11.026","volume":"58","author":"JW Polania","year":"2025","unstructured":"Polania JW, Hoyt-Miggelbrink A, Tomaszewski WH, Wachsmuth LP, Lorrey SJ, Wilkinson DS, et al. Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion. Immunity. 2025;58(2):232-246.e6. https:\/\/doi.org\/10.1016\/j.immuni.2024.11.026.","journal-title":"Immunity"},{"key":"502_CR111","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41586-023-06511-9","volume":"621","author":"C Wang","year":"2023","unstructured":"Wang C, Zheng X, Zhang J, Jiang X, Wang J, Li Y, et al. CD300ld on neutrophils is required for tumour-driven immune suppression. Nature. 2023;621:830\u20139. https:\/\/doi.org\/10.1038\/s41586-023-06511-9.","journal-title":"Nature"},{"issue":"11","key":"502_CR112","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/j.ccell.2024.11.005","volume":"42","author":"I-M Launonen","year":"2024","unstructured":"Launonen I-M, Niemiec I, Hincapie-Otero M, Erkan EP, Junquera A, Afenteva D, et al. Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer. Cancer Cell. 2024;42(11):2045-2063.e10. https:\/\/doi.org\/10.1016\/j.ccell.2024.11.005.","journal-title":"Cancer Cell"},{"issue":"1","key":"502_CR113","doi-asserted-by":"publisher","first-page":"8923","DOI":"10.1038\/s41467-025-63659-w","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, Li J, Song D, Wu Y, Liu J, Yi Z, et al. AEBP1 drives fibroblast-mediated T cell dysfunction in tumors. Nat Commun. 2025;16(1):8923. https:\/\/doi.org\/10.1038\/s41467-025-63659-w.","journal-title":"Nat Commun"},{"issue":"5","key":"502_CR114","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.cell.2026.01.001","volume":"189","author":"S-W Zhang","year":"2026","unstructured":"Zhang S-W, Wang H, Xiao Y, Liu L-T, Shen M, Wang Z, et al. Sensory neurons drive immune exclusion by stimulating a dense extracellular matrix in the breast cancer tumor microenvironment. Cell. 2026;189(5):1039-1055.e20. https:\/\/doi.org\/10.1016\/j.cell.2026.01.001.","journal-title":"Cell"},{"issue":"11","key":"502_CR115","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/j.ccell.2024.10.014","volume":"42","author":"K H\u00e4nggi","year":"2024","unstructured":"H\u00e4nggi K, Li J, Gangadharan A, Liu X, Celias DP, Osunmakinde O, et al. Interleukin-1\u03b1 release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity. Cancer Cell. 2024;42(11):2015-2031.e11. https:\/\/doi.org\/10.1016\/j.ccell.2024.10.014.","journal-title":"Cancer Cell"},{"issue":"11","key":"502_CR116","doi-asserted-by":"publisher","first-page":"e009165","DOI":"10.1136\/jitc-2024-009165","volume":"12","author":"C Lu","year":"2024","unstructured":"Lu C, Gao Z, Wu D, Zheng J, Hu C, Huang D, et al. Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect. J Immunother Cancer. 2024;12(11):e009165. https:\/\/doi.org\/10.1136\/jitc-2024-009165.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"502_CR117","doi-asserted-by":"publisher","first-page":"e190557","DOI":"10.1172\/JCI190557","volume":"136","author":"H Li","year":"2026","unstructured":"Li H, Zhang Y, Lin J, Zeng J, Liang X, Xu L, et al. Tumor-derived neutrophil extracellular trap-associated DNA impairs treatment efficacy in breast cancer via CCDC25-dependent epithelial-mesenchymal transition. J Clin Invest. 2026;136(5):e190557. https:\/\/doi.org\/10.1172\/JCI190557.","journal-title":"J Clin Invest"},{"issue":"2","key":"502_CR118","doi-asserted-by":"publisher","first-page":"e013247","DOI":"10.1136\/jitc-2025-013247","volume":"14","author":"L Gao","year":"2026","unstructured":"Gao L, Wang B, Liu H, Liu P, Liu L, Han J, et al. Targeting PKMYT1 enhances antitumor immune responses to PD-L1 blockade in castration-resistant prostate cancer. J Immunother Cancer. 2026;14(2):e013247. https:\/\/doi.org\/10.1136\/jitc-2025-013247.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"502_CR119","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-025-01210-2","volume":"15","author":"AG Solimando","year":"2025","unstructured":"Solimando AG, Palma FD, Desantis V, Vacca A, Svelto M, Pisani F, et al. Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma. Blood Cancer J. 2025;15(1):45. https:\/\/doi.org\/10.1038\/s41408-025-01210-2.","journal-title":"Blood Cancer J"},{"issue":"32","key":"502_CR120","doi-asserted-by":"publisher","first-page":"e2404994","DOI":"10.1002\/advs.202404994","volume":"11","author":"X He","year":"2024","unstructured":"He X, Zhong L, Wang N, Zhao B, Wang Y, Wu X, et al. Gastric Cancer Actively Remodels Mechanical Microenvironment to Promote Chemotherapy Resistance via MSCs-Mediated Mitochondrial Transfer. Adv Sci. 2024;11(32):e2404994. https:\/\/doi.org\/10.1002\/advs.202404994.","journal-title":"Adv Sci"},{"issue":"8","key":"502_CR121","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.7150\/thno.103722","volume":"15","author":"J Wang","year":"2025","unstructured":"Wang J, Liu L, Gao X, Liu X, Dai Y, Mao Z, et al. A novel pathway for stemness propagation and chemoresistance in non-small cell lung cancer via phosphorylated PKM2-loaded small extracellular vesicles. Theranostics. 2025;15(8):3439\u201361. https:\/\/doi.org\/10.7150\/thno.103722.","journal-title":"Theranostics"},{"issue":"1","key":"502_CR122","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41423-025-01371-x","volume":"23","author":"Y Wang","year":"2026","unstructured":"Wang Y, Zhang S, Yang Y, Wang Y, Zhang Y, Liu M, et al. PA28\u03b3-containing tumor-derived exosomes promote T-cell dysfunction in head and neck squamous cell carcinoma. Cell Mol Immunol. 2026;23(1):63\u201378. https:\/\/doi.org\/10.1038\/s41423-025-01371-x.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"502_CR123","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13046-024-03087-8","volume":"43","author":"V Del Vecchio","year":"2024","unstructured":"Del Vecchio V, Rehman A, Panda SK, Torsi M, Marigliano M, Nicoletti MM, et al. Mitochondrial transfer from Adipose stem cells to breast cancer cells drives multi-drug resistance. J Exp Clin Cancer Res. 2024;43(1):166. https:\/\/doi.org\/10.1186\/s13046-024-03087-8.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"502_CR124","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1158\/0008-5472.CAN-25-0433","volume":"86","author":"T Liu","year":"2025","unstructured":"Liu T, Huang S, Li Z, Li J, Sun Q, Wang Q, et al. Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer. Cancer Res. 2025;86(7):1215\u201331. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-0433.","journal-title":"Cancer Res"},{"issue":"12","key":"502_CR125","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/s41563-024-01961-6","volume":"23","author":"N Gong","year":"2024","unstructured":"Gong N, Zhong W, Alameh M-G, Han X, Xue L, El-Mayta R, et al. Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery. Nat Mater. 2024;23(12):1736\u201347. https:\/\/doi.org\/10.1038\/s41563-024-01961-6.","journal-title":"Nat Mater"},{"issue":"18","key":"502_CR126","doi-asserted-by":"publisher","first-page":"e2417626122","DOI":"10.1073\/pnas.2417626122","volume":"122","author":"P Du","year":"2025","unstructured":"Du P, Tang K, Chen X, Xin Y, Hu B, Meng J, et al. Intercellular contractile force attenuates chemosensitivity through Notch-MVP-mediated nuclear drug export. Proc Natl Acad Sci U S A. 2025;122(18):e2417626122. https:\/\/doi.org\/10.1073\/pnas.2417626122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"49","key":"502_CR127","doi-asserted-by":"publisher","first-page":"34107","DOI":"10.1021\/acsnano.4c09996","volume":"18","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Xu M, Wu J, Qian K, Yang P, Zhou L, et al. Carcinoma-Astrocyte Gap Junction Interruption by a Dual-Targeted Biomimetic Liposomal System to Attenuate Chemoresistance and Treat Brain Metastasis. ACS Nano. 2024;18(49):34107\u201325. https:\/\/doi.org\/10.1021\/acsnano.4c09996.","journal-title":"ACS Nano"},{"issue":"1","key":"502_CR128","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41392-025-02307-7","volume":"10","author":"Z Wang","year":"2025","unstructured":"Wang Z, Gu Y, Liu Y, Wang Z, Chen X, Wang H, et al. Phosphorylated Toll-like receptor 3 nuclear translocation in cancer cell promotes metastasis and chemoresistance. Signal Transduct Target Ther. 2025;10(1):178. https:\/\/doi.org\/10.1038\/s41392-025-02307-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"502_CR129","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ccell.2023.03.008","volume":"41","author":"A Mousset","year":"2023","unstructured":"Mousset A, Leorgne E, Bourget I, Lopez P, Jenovai K, Cherfils-Vicini J, et al. Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-\u03b2 activation. Cancer Cell. 2023;41(5):757-775.e10. https:\/\/doi.org\/10.1016\/j.ccell.2023.03.008.","journal-title":"Cancer Cell"},{"issue":"18","key":"502_CR130","doi-asserted-by":"publisher","first-page":"e2320591121","DOI":"10.1073\/pnas.2320591121","volume":"121","author":"J Bie","year":"2024","unstructured":"Bie J, Li Y, Song C, Weng Q, Zhao L, Su L, et al. LAMTOR1 ablation impedes cGAS degradation caused by chemotherapy and promotes antitumor immunity. Proc Natl Acad Sci U S A. 2024;121(18):e2320591121. https:\/\/doi.org\/10.1073\/pnas.2320591121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8072","key":"502_CR131","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41586-025-08994-0","volume":"643","author":"A Piffko","year":"2025","unstructured":"Piffko A, Yang K, Panda A, Heide J, Tesak K, Wen C, et al. Radiation-induced amphiregulin drives tumour metastasis. Nature. 2025;643(8072):810\u20139. https:\/\/doi.org\/10.1038\/s41586-025-08994-0.","journal-title":"Nature"},{"issue":"32","key":"502_CR132","doi-asserted-by":"publisher","first-page":"e2304609","DOI":"10.1002\/advs.202304609","volume":"11","author":"J Ji","year":"2024","unstructured":"Ji J, Ding K, Cheng B, Zhang X, Luo T, Huang B, et al. Radiotherapy-Induced Astrocyte Senescence Promotes an Immunosuppressive Microenvironment in Glioblastoma to Facilitate Tumor Regrowth. Adv Sci. 2024;11(32):e2304609. https:\/\/doi.org\/10.1002\/advs.202304609.","journal-title":"Adv Sci"},{"issue":"1","key":"502_CR133","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41392-023-01462-z","volume":"8","author":"S Guo","year":"2023","unstructured":"Guo S, Yao Y, Tang Y, Xin Z, Wu D, Ni C, et al. Radiation-induced tumor immune microenvironments and potential targets for combination therapy. Signal Transduct Target Ther. 2023;8(1):432. https:\/\/doi.org\/10.1038\/s41392-023-01462-z.","journal-title":"Signal Transduct Target Ther"},{"issue":"8030","key":"502_CR134","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/s41586-025-09303-5","volume":"645","author":"J Heide","year":"2025","unstructured":"Heide J, Bilecz AJ, Patnaik S, Allega MF, Donle L, Yang K, et al. NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity. Nature. 2025;645(8030):1051\u20139. https:\/\/doi.org\/10.1038\/s41586-025-09303-5.","journal-title":"Nature"},{"key":"502_CR135","doi-asserted-by":"publisher","unstructured":"Trotta R, Rivis S, Zhao S, Orban M-P, Cafarello ST, Charatsidou I, et al. Activated T cells break tumor immunosuppression by macrophage re-education. Cancer Discov. 2025;15(11):OF1\u201327. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0415.","DOI":"10.1158\/2159-8290.CD-24-0415"},{"issue":"10","key":"502_CR136","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/j.jtho.2023.06.012","volume":"18","author":"K Haratani","year":"2023","unstructured":"Haratani K, Nakamura A, Mamesaya N, Mitsuoka S, Yoneshima Y, Saito R, et al. Tumor microenvironment landscape of nsclc reveals resistance mechanisms for programmed death-ligand 1 blockade after chemoradiotherapy: a multicenter prospective biomarker study (WJOG11518L: SUBMARINE). J Thorac Oncol. 2023;18(10):1334\u201350. https:\/\/doi.org\/10.1016\/j.jtho.2023.06.012.","journal-title":"J Thorac Oncol"},{"issue":"7942","key":"502_CR137","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41586-023-06225-y","volume":"619","author":"SA Cohen","year":"2023","unstructured":"Cohen SA, Liu MC, Aleshin A, et al. Practical recommendations for using ctDNA in clinical decision making. Nature. 2023;619(7942):259\u201368. https:\/\/doi.org\/10.1038\/s41586-023-06225-y.","journal-title":"Nature"},{"key":"502_CR138","doi-asserted-by":"publisher","first-page":"105109","DOI":"10.1016\/j.ebiom.2024.105109","volume":"103","author":"J Zheng","year":"2024","unstructured":"Zheng J, Qin C, Wang Q, Tian D, Chen Z, et al. Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis. EBioMedicine. 2024;103:105109. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105109.","journal-title":"EBioMedicine"},{"issue":"7958","key":"502_CR139","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","volume":"616","author":"C Abbosh","year":"2023","unstructured":"Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. 2023;616(7958):553\u201362. https:\/\/doi.org\/10.1038\/s41586-023-05776-4.","journal-title":"Nature"},{"issue":"2","key":"502_CR140","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1158\/1078-0432.CCR-23-1469","volume":"30","author":"JC Murray","year":"2023","unstructured":"Murray JC, Sivapalan L, Hummelink K, Balan A, White JR, Niknafs N, et al. Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer. Clin Cancer Res. 2023;30(2):389\u2013403. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1469.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"502_CR141","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2024-201701","volume":"144","author":"R Gunaratne","year":"2024","unstructured":"Gunaratne R, Zhou C, Tai JW, Kim S, Tanaka K, Rajaram S, et al. Circulating tumor DNA (ctDNA) enables superior and universal measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML) highly predictive of relapse free and overall survival. Blood. 2024;144(Suppl 1):2955. https:\/\/doi.org\/10.1182\/blood-2024-201701.","journal-title":"Blood"},{"issue":"11","key":"502_CR142","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","volume":"30","author":"Y Nakamura","year":"2024","unstructured":"Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M, et al. CtDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med. 2024;30(11):3272\u201383. https:\/\/doi.org\/10.1038\/s41591-024-03254-6.","journal-title":"Nat Med"},{"issue":"1","key":"502_CR143","doi-asserted-by":"publisher","first-page":"8923","DOI":"10.1038\/s41467-025-65432-5","volume":"16","author":"MJM Magbanua","year":"2025","unstructured":"Magbanua MJM, Manon NA, Wolf DM, Rivero-Hinojosa S, Ahmed Z, Sayaman RW, et al. Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors. Nat Commun. 2025;16(1):8923. https:\/\/doi.org\/10.1038\/s41467-025-65432-5.","journal-title":"Nat Commun"},{"issue":"4","key":"502_CR144","doi-asserted-by":"publisher","first-page":"e70483","DOI":"10.1002\/mco2.70483","volume":"6","author":"L Liu","year":"2025","unstructured":"Liu L, Liang W, Cao W, Wang H, Liang H, Huang L, et al. Personalized and tumor informed circulating tumor DNA assay for molecular residual disease monitoring of solid malignancies. MedComm. 2025;6(4):e70483. https:\/\/doi.org\/10.1002\/mco2.70483.","journal-title":"MedComm"},{"issue":"1","key":"502_CR145","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41392-025-02445-y","volume":"10","author":"Y Yang","year":"2025","unstructured":"Yang Y, Wu Y, Zhao J, Zhang T, Fei K, Zhao X, et al. Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients. Signal Transduct Target Ther. 2025;10(1):312. https:\/\/doi.org\/10.1038\/s41392-025-02445-y.","journal-title":"Signal Transduct Target Ther"},{"issue":"8053","key":"502_CR146","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s41586-026-10244-w","volume":"638","author":"J Lv","year":"2026","unstructured":"Lv J, Zheng D-X, Liang J-H, Zhang N, Ye Z-L, Xu X-D, et al. Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma. Nature. 2026;638(8053):1124\u201332. https:\/\/doi.org\/10.1038\/s41586-026-10244-w.","journal-title":"Nature"},{"key":"502_CR147","doi-asserted-by":"publisher","unstructured":"Cai J, Cao Y-B, Leung EL-H, et al. Detection of Single Non-small Cell Lung Cancer Cell Multidrug Resistance with Single-Cell Bioanalyzer. Methods Mol Biol. 2023;2689:1\u201311. https:\/\/doi.org\/10.1007\/978-1-0716-3323-6_1.","DOI":"10.1007\/978-1-0716-3323-6_1"},{"issue":"39","key":"502_CR148","doi-asserted-by":"publisher","first-page":"15753","DOI":"10.1021\/acs.analchem.5c01558","volume":"97","author":"H Pei","year":"2025","unstructured":"Pei H, Si H, Du D, Li L, Tang B, et al. Time-Resolved Quantification of Single-Cell Extracellular Vesicles Secretion for Drug Resistance Evaluation. Anal Chem. 2025;97(39):15753\u201361. https:\/\/doi.org\/10.1021\/acs.analchem.5c01558.","journal-title":"Anal Chem"},{"issue":"1","key":"502_CR149","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12943-024-02040-9","volume":"23","author":"Y Jin","year":"2024","unstructured":"Jin Y, Zuo Y, Li G, Liu W, Pan Y, Fan T, et al. Advances in spatial transcriptomics and its applications in cancer research. Mol Cancer. 2024;23(1):112. https:\/\/doi.org\/10.1186\/s12943-024-02040-9.","journal-title":"Mol Cancer"},{"key":"502_CR150","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-cancerbio-070924-120742","volume":"8","author":"Y-T Chou","year":"2024","unstructured":"Chou Y-T, Allegakoen P, Bivona TG, et al. Targeting Minimal Residual Disease. Annu Rev Cancer Biol. 2024;8:123\u201345. https:\/\/doi.org\/10.1146\/annurev-cancerbio-070924-120742.","journal-title":"Annu Rev Cancer Biol"},{"issue":"12","key":"502_CR151","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/14728222.2023.2225767","volume":"27","author":"D Wu","year":"2023","unstructured":"Wu D, Tian S, Zhu W, et al. Modulating multidrug resistance to drug-based antitumor therapies through NF-\u03baB signaling pathway: mechanisms and perspectives. Expert Opin Ther Targets. 2023;27(12):503\u201315. https:\/\/doi.org\/10.1080\/14728222.2023.2225767.","journal-title":"Expert Opin Ther Targets"},{"issue":"7","key":"502_CR152","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.3390\/ijms26073438","volume":"26","author":"P Ferrari","year":"2025","unstructured":"Ferrari P, Schiavone ML, Scatena C, Nicolini A, et al. Molecular mechanisms and therapeutic strategies to overcome resistance to endocrine therapy and CDK4\/6 inhibitors in advanced ER\/HER2- breast cancer. Int J Mol Sci. 2025;26(7):3438. https:\/\/doi.org\/10.3390\/ijms26073438.","journal-title":"Int J Mol Sci"},{"issue":"28","key":"502_CR153","doi-asserted-by":"publisher","first-page":"e2303394","DOI":"10.1002\/adhm.202303394","volume":"13","author":"D Liu","year":"2024","unstructured":"Liu D, Tian H, Li H, Nie J, Han Z, Tang G, et al. Radiotherapy Resistance of 3D Bioprinted Glioma via ITGA2\/p-AKT Signaling Pathway. Adv Healthc Mater. 2024;13(28):e2303394. https:\/\/doi.org\/10.1002\/adhm.202303394.","journal-title":"Adv Healthc Mater"},{"issue":"11","key":"502_CR154","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41422-025-01180-x","volume":"35","author":"X Li","year":"2025","unstructured":"Li X, Gardner EE, Molina-Pinolo S, Wilhelm C, Mu P, Quintanal-Villalonga A, et al. Lineage plasticity and histological transformation: tumor histology as a spectrum. Cell Res. 2025;35(11):803\u201323. https:\/\/doi.org\/10.1038\/s41422-025-01180-x.","journal-title":"Cell Res"},{"issue":"12","key":"502_CR155","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1038\/s41590-024-02032-3","volume":"25","author":"P Jauregui","year":"2024","unstructured":"Jauregui P, et al. IL-4 promotes immunotherapy resistance. Nat Immunol. 2024;25(12):2169. https:\/\/doi.org\/10.1038\/s41590-024-02032-3.","journal-title":"Nat Immunol"},{"key":"502_CR156","doi-asserted-by":"publisher","unstructured":"Giri S, Lamichhane G, Pandey J, Khadayat R, C SK, Devkota HP, et al. Immune Modulation and Immunotherapy in Solid Tumors: Mechanisms of Resistance and Potential Therapeutic Strategies. Int J Mol Sci. 2025;26(7):2923. https:\/\/doi.org\/10.3390\/ijms26072923.","DOI":"10.3390\/ijms26072923"},{"issue":"1","key":"502_CR157","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12943-025-02400-z","volume":"24","author":"K Mandal","year":"2025","unstructured":"Mandal K, Barik GK, Santra MK, et al. Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions. Mol Cancer. 2025;24(1):112. https:\/\/doi.org\/10.1186\/s12943-025-02400-z.","journal-title":"Mol Cancer"},{"issue":"12","key":"502_CR158","doi-asserted-by":"publisher","first-page":"102315","DOI":"10.1016\/j.xcrm.2025.102315","volume":"6","author":"K Kang","year":"2025","unstructured":"Kang K, Liu S, Yao Z, Xue J, Lu Y. Addressing clinical needs in NSCLC immunotherapy: mechanisms of resistance and promising combination strategies. Cell Rep Med. 2025;6(12):102315. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102315.","journal-title":"Cell Rep Med"},{"issue":"1","key":"502_CR159","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","volume":"22","author":"K Pantel","year":"2024","unstructured":"Pantel K, Alix-Panabi\u00e8res C. Minimal residual disease as a target for liquid biopsy in patients with solid tumours. Nat Rev Clin Oncol. 2024;22(1):65\u201377. https:\/\/doi.org\/10.1038\/s41571-024-00967-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"502_CR160","doi-asserted-by":"publisher","first-page":"101360","DOI":"10.1016\/j.drup.2026.101360","volume":"85","author":"M Zhang","year":"2026","unstructured":"Zhang M, Li L, Pu H, Wang Y, Zhang X, Guo X, et al. Tumor immune organoids in immunotherapy resistance and drug screening. Drug Resist Updat. 2026;85:101360. https:\/\/doi.org\/10.1016\/j.drup.2026.101360.","journal-title":"Drug Resist Updat"},{"key":"502_CR161","doi-asserted-by":"publisher","unstructured":"Zhang Y, Gao H, Tang A, Lyu H, Fan Z, Guo J, et al. CSN6 promotes pancreatic cancer progression and gemcitabine resistance via antagonizing DCAF1-mediated ubiquitination of NPM1. Adv Sci. 2025;13(28):e2510210. https:\/\/doi.org\/10.1002\/advs.202510210.","DOI":"10.1002\/advs.202510210"},{"issue":"12","key":"502_CR162","doi-asserted-by":"publisher","first-page":"101162","DOI":"10.1016\/j.xcrm.2023.101162","volume":"4","author":"Y Li","year":"2023","unstructured":"Li Y, Tang S, Shi X, Lv J, Wu X, Zhang Y, et al. Metabolic classification suggests the GLUT1\/ALDOB\/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Cell Rep Med. 2023;4(12):101162. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101162.","journal-title":"Cell Rep Med"},{"issue":"1","key":"502_CR163","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41698-025-01046-w","volume":"9","author":"R Bhatia","year":"2025","unstructured":"Bhatia R, Khan I, Li X, Gautam S, Seshacharyulu P, Alsafwani ZW, et al. Targeting cancer-associated fibroblast-driven LIF\/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer. npj Precis Oncol. 2025;9(1):45. https:\/\/doi.org\/10.1038\/s41698-025-01046-w.","journal-title":"npj Precis Oncol"},{"issue":"1","key":"502_CR164","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41419-025-08105-x","volume":"16","author":"D Qi","year":"2025","unstructured":"Qi D, Qin Y, Zhu H, Li Y, Han S, et al. Resistance of first-line targeted drugs in hepatocellular carcinoma: the epigenetic regulation mechanisms. Cell Death Dis. 2025;16(1):875. https:\/\/doi.org\/10.1038\/s41419-025-08105-x.","journal-title":"Cell Death Dis"},{"issue":"4","key":"502_CR165","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1097\/HEP.0000000000001474","volume":"82","author":"Q Huang","year":"2025","unstructured":"Huang Q, Wang W, Ge Q, Xu D, Dong R, Chang R, et al. NEK7 induced phosphorylation of EGFR on serine 1070 drive the acquired lenvatinib resistance in hepatocellular carcinoma. Hepatology. 2025;82(4):1124\u201336. https:\/\/doi.org\/10.1097\/HEP.0000000000001474.","journal-title":"Hepatology"},{"key":"502_CR166","doi-asserted-by":"publisher","unstructured":"Jin X, Dong H, Wang J, Ou G, Lai X, Tian X, et al. HBx Facilitates Drug Resistance in Hepatocellular Carcinoma via CD133-regulated Self-renewal of Liver Cancer Stem Cells. J Clin Transl Hepatol. 2024;12(4):678\u201389. https:\/\/doi.org\/10.14218\/JCTH.2024.00259.","DOI":"10.14218\/JCTH.2024.00259"},{"issue":"1","key":"502_CR167","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41572-024-00500-6","volume":"10","author":"JM Llovet","year":"2024","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Author Correction: Hepatocellular carcinoma. Nat Rev Dis Primers. 2024;10(1):10. https:\/\/doi.org\/10.1038\/s41572-024-00500-6.","journal-title":"Nat Rev Dis Primers"},{"issue":"23","key":"502_CR168","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore KN, Angelergues A, Konecny GE, Garcia Y, Banerjee S, Lorusso D, et al. Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer. N Engl J Med. 2023;389(23):2162\u201374. https:\/\/doi.org\/10.1056\/NEJMoa2309169.","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"502_CR169","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1200\/JCO.2021.39.15_suppl.5516","volume":"39","author":"SL Wethington","year":"2021","unstructured":"Wethington SL, Shah PD, Martin LP, Tanyi JL, Latif NA, Morgan MA, et al. Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer. J Clin Oncol. 2021;39(15_suppl):5516\u20135516. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.5516.","journal-title":"J Clin Oncol"},{"issue":"8","key":"502_CR170","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41419-023-06064-9","volume":"14","author":"S Di Agostino","year":"2023","unstructured":"Di Agostino S, Canu V, Donzelli S, Pulito C, Sacconi A, Ganci F, et al. HSF-1\/miR-145-5p transcriptional axis enhances hyperthermic intraperitoneal chemotherapy efficacy on peritoneal ovarian carcinosis. Cell Death Dis. 2023;14(8):535. https:\/\/doi.org\/10.1038\/s41419-023-06064-9.","journal-title":"Cell Death Dis"},{"issue":"1","key":"502_CR171","doi-asserted-by":"publisher","first-page":"8234","DOI":"10.1038\/s41467-023-39817-3","volume":"14","author":"M Haake","year":"2023","unstructured":"Haake M, Haack B, Schafer T, Harter PN, Mattavelli G, Eiring P, et al. Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment. Nat Commun. 2023;14(1):8234. https:\/\/doi.org\/10.1038\/s41467-023-39817-3.","journal-title":"Nat Commun"},{"issue":"9","key":"502_CR172","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","volume":"29","author":"A VanderWalde","year":"2023","unstructured":"VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, et al. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med. 2023;29(9):2278\u201385. https:\/\/doi.org\/10.1038\/s41591-023-02498-y.","journal-title":"Nat Med"},{"key":"502_CR173","doi-asserted-by":"publisher","unstructured":"Gonzalez-Cao M, Casas CM de las, Oramas J, Berciano-Guerrero MA, Cruz L de la, Cerezuela P, et al. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Nat Commun. 2021;12(1):7234. https:\/\/doi.org\/10.1038\/s41467-021-26572-6.","DOI":"10.1038\/s41467-021-26572-6"},{"issue":"1","key":"502_CR174","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030.","journal-title":"N Engl J Med"},{"issue":"21","key":"502_CR175","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, Janne PA, Cheng Y, Yang JC-H, Yanagitani N, Kim S-W, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389(21):1935\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2306434.","journal-title":"N Engl J Med"},{"issue":"16","key":"502_CR176","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","volume":"391","author":"BC Cho","year":"2024","unstructured":"Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee J-S, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024;391(16):1486\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2403614.","journal-title":"N Engl J Med"},{"issue":"5","key":"502_CR177","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.tips.2023.03.003","volume":"44","author":"Y Fang","year":"2023","unstructured":"Fang Y, Wang S, Han S, Zhao Y, Yu C, Liu H, et al. Targeted protein degrader development for cancer: advances, challenges, and opportunities. Trends Pharmacol Sci. 2023;44(5):303\u201317. https:\/\/doi.org\/10.1016\/j.tips.2023.03.003.","journal-title":"Trends Pharmacol Sci"},{"key":"502_CR178","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s41588-025-02187-1","volume":"57","author":"A Gupta","year":"2025","unstructured":"Gupta A, Gazzo A, Selenica P, Safonov A, Pareja F, da Silva EM, et al. APOBEC3 mutagenesis drives therapy resistance in breast cancer. Nat Genet. 2025;57:1452\u201362. https:\/\/doi.org\/10.1038\/s41588-025-02187-1.","journal-title":"Nat Genet"},{"issue":"1","key":"502_CR179","doi-asserted-by":"publisher","first-page":"8923","DOI":"10.1038\/s41467-024-54145-w","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, Venet D, Lifrange F, Larsimont D, Rediti M, Stenbeck L, et al. Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications. Nat Commun. 2024;15(1):8923. https:\/\/doi.org\/10.1038\/s41467-024-54145-w.","journal-title":"Nat Commun"},{"issue":"8","key":"502_CR180","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1016\/j.apsb.2025.04.006","volume":"15","author":"S Wu","year":"2025","unstructured":"Wu S, Tang Q, Fang W, Sun Z, Zhang M, Liu E, et al. Targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery. Acta Pharm Sin B. 2025;15(8):3226\u201342. https:\/\/doi.org\/10.1016\/j.apsb.2025.04.006.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"502_CR181","doi-asserted-by":"publisher","first-page":"2333790","DOI":"10.1080\/19490976.2024.2333790","volume":"16","author":"N Wang","year":"2024","unstructured":"Wang N, Zhang L, Leng X-X, Xie Y-L, Kang Z-R, Zhao L-C, et al. Fusobacterium nucleatum induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the Hippo pathway. Gut Microbes. 2024;16(1):2333790. https:\/\/doi.org\/10.1080\/19490976.2024.2333790.","journal-title":"Gut Microbes"},{"issue":"2","key":"502_CR182","doi-asserted-by":"publisher","first-page":"189108","DOI":"10.1016\/j.bbcan.2024.189108","volume":"1879","author":"W Ye","year":"2024","unstructured":"Ye W, Lu X, Qiao Y, Ou W-B. Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024;1879(2):189108. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189108.","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"1","key":"502_CR183","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41419-026-08413-w","volume":"17","author":"X Zhang","year":"2026","unstructured":"Zhang X, Fei Y, Xie C, Li T, Niu B, Yang Z, et al. Cancer-associated fibroblasts (CAFs) derived from MFAP2 promote CRC proliferation and metastasis while suppressing CD8+ T cell-mediated antitumor immunity. Cell Death Dis. 2026;17(1):159. https:\/\/doi.org\/10.1038\/s41419-026-08413-w.","journal-title":"Cell Death Dis"},{"issue":"Suppl 5","key":"502_CR184","doi-asserted-by":"publisher","first-page":"v34","DOI":"10.1093\/neuonc\/noad179.0134","volume":"25","author":"F Jamali","year":"2023","unstructured":"Jamali F, Lan K, Sabri S, Abdulkarim B. STEM-08. Overcoming glioblastoma stem cell resistance to radiation through targeting thioredoxin reductase 1. Neuro-oncol. 2023;25(Suppl 5):v34. https:\/\/doi.org\/10.1093\/neuonc\/noad179.0134.","journal-title":"Neuro-oncol"},{"key":"502_CR185","doi-asserted-by":"publisher","first-page":"114583","DOI":"10.1016\/j.addr.2022.114583","volume":"191","author":"CM Gorick","year":"2022","unstructured":"Gorick CM, Breza VR, Nowak KM, Cheng VWT, Fisher DG, Debski AC, et al. Applications of focused ultrasound-mediated blood-brain barrier opening. Adv Drug Deliv Rev. 2022;191:114583. https:\/\/doi.org\/10.1016\/j.addr.2022.114583.","journal-title":"Adv Drug Deliv Rev"},{"issue":"28","key":"502_CR186","doi-asserted-by":"publisher","first-page":"e2513632","DOI":"10.1002\/advs.202513632","volume":"13","author":"M Yang","year":"2025","unstructured":"Yang M, Niu W, Wang Y, Chen P, Mu M, Zhang X, et al. Low YTHDC1 expression upregulates FSCN1 to promote nuclear F-actin formation and facilitate double-strand DNA breaks repair in TMZ-resistant glioblastoma. Adv Sci. 2025;13(28):e2513632. https:\/\/doi.org\/10.1002\/advs.202513632.","journal-title":"Adv Sci"},{"issue":"1","key":"502_CR187","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12943-025-02385-9","volume":"24","author":"J Zhang","year":"2025","unstructured":"Zhang J, Lv S, Peng X, Liu H, Guo J, Liu Z, et al. CircERC1 facilitates chemoresistance through inhibiting pyroptosis and remodeling extracellular matrix in pancreatic cancer. Mol Cancer. 2025;24(1):112. https:\/\/doi.org\/10.1186\/s12943-025-02385-9.","journal-title":"Mol Cancer"},{"issue":"1","key":"502_CR188","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13058-024-01788-8","volume":"26","author":"F Derouane","year":"2024","unstructured":"Derouane F, Desgres M, Moroni C, Ambroise J, Berliere M, Bockstal MRV, et al. Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers. Breast Cancer Res. 2024;26(1):45. https:\/\/doi.org\/10.1186\/s13058-024-01788-8.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"502_CR189","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41419-025-08226-3","volume":"17","author":"MR Saathoff","year":"2025","unstructured":"Saathoff MR, Chojak R, Chen RX, Kazi HA, Faisal UH, Shireman JM, et al. LMNA-PRKDC axis enhances DNA repair and promotes chemoresistance in glioblastoma. Cell Death Dis. 2025;17(1):50. https:\/\/doi.org\/10.1038\/s41419-025-08226-3.","journal-title":"Cell Death Dis"},{"issue":"3","key":"502_CR190","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ymthe.2025.01.023","volume":"33","author":"X Liu","year":"2025","unstructured":"Liu X, Yang J, Huang S, Hong Y, Zhu Y, Wang J, et al. Pancreatic cancer-derived extracellular vesicles enhance chemoresistance by delivering KRASG12D protein to cancer-associated fibroblasts. Mol Ther. 2025;33(3):1134\u201353. https:\/\/doi.org\/10.1016\/j.ymthe.2025.01.023.","journal-title":"Mol Ther"},{"issue":"17","key":"502_CR191","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1097\/CM9.0000000000003679","volume":"138","author":"X Li","year":"2025","unstructured":"Li X, Yu G, Zhong X, Zhong J, Chen X, Chen Q, et al. P4HA1 mediates YAP hydroxylation and accelerates collagen synthesis in temozolomide-resistant glioblastoma. Chin Med J (Engl). 2025;138(17):1991\u20132005. https:\/\/doi.org\/10.1097\/CM9.0000000000003679.","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"502_CR192","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s43018-025-01097-9","volume":"7","author":"PM Moreno-Sanchez","year":"2026","unstructured":"Moreno-Sanchez PM, Rezaeipour M, Inderberg EM, Platten M, Golebiewska A, et al. Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity. Nat Cancer. 2026;7(3):412\u201325. https:\/\/doi.org\/10.1038\/s43018-025-01097-9.","journal-title":"Nat Cancer"},{"issue":"1","key":"502_CR193","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40364-024-00719-1","volume":"13","author":"X-Y Sui","year":"2025","unstructured":"Sui X-Y, Cao S-W, Song X-Q, Liu X-Y, Chen C, Yan Q, et al. MORF4L2 induces immunosuppressive microenvironment and immunotherapy resistance through GRHL2\/MORF4L2\/H4K12Ac\/CSF1 axis in triple-negative breast cancer. Biomark Res. 2025;13(1):45. https:\/\/doi.org\/10.1186\/s40364-024-00719-1.","journal-title":"Biomark Res"},{"issue":"1","key":"502_CR194","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41392-025-02472-9","volume":"10","author":"W Zhang","year":"2025","unstructured":"Zhang W, Gai Y, Qiao M, Rowicki M, Wei Y, Hang X, et al. Family with sequence similarity 114 member A1 orchestrates immune evasion in triple-negative breast cancer. Signal Transduct Target Ther. 2025;10(1):178. https:\/\/doi.org\/10.1038\/s41392-025-02472-9.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"502_CR195","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-025-03776-7","volume":"31","author":"S-Y Wu","year":"2025","unstructured":"Wu S-Y, Jin X, Liu Y, Wang Z-Y, Zuo W-J, Ma D, et al. Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial. Nat Med. 2025;31(8):2124\u201332. https:\/\/doi.org\/10.1038\/s41591-025-03776-7.","journal-title":"Nat Med"},{"issue":"28","key":"502_CR196","doi-asserted-by":"publisher","first-page":"e2502915","DOI":"10.1002\/advs.202502915","volume":"12","author":"H Chang","year":"2025","unstructured":"Chang H, Hou J, Hu X, Hou N, Xu M, Du Y, et al. Sanggenol L enhances temozolomide drug sensitivity by inhibiting mitophagy and inducing apoptosis through the regulation of the TRIM16-OPTN Axis in Glioblastoma. Adv Sci. 2025;12(28):e2502915. https:\/\/doi.org\/10.1002\/advs.202502915.","journal-title":"Adv Sci"},{"issue":"11","key":"502_CR197","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41589-024-01612-6","volume":"20","author":"Z Li","year":"2024","unstructured":"Li Z, Xu Z, Chen W, Du X, Ou C, Luo Z, et al. Tumor-repopulating cells evade ferroptosis via PCK2-dependent phospholipid remodeling. Nat Chem Biol. 2024;20(11):1341\u201352. https:\/\/doi.org\/10.1038\/s41589-024-01612-6.","journal-title":"Nat Chem Biol"},{"issue":"8053","key":"502_CR198","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41586-025-09710-8","volume":"649","author":"K Wu","year":"2025","unstructured":"Wu K, Vaughan AJ, Bossowski JP, Hao Y, Ziogou A, Kim SM, et al. Targeting FSP1 triggers ferroptosis in lung cancer. Nature. 2025;649(8053):487\u201395. https:\/\/doi.org\/10.1038\/s41586-025-09710-8.","journal-title":"Nature"},{"issue":"6","key":"502_CR199","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.ccell.2025.03.031","volume":"43","author":"G Lei","year":"2025","unstructured":"Lei G, Sun M, Cheng J, Ye R, Lu Z, Horbath A, et al. Radiotherapy promotes cuproptosis and synergizes with cuproptosis inducers to overcome tumor radioresistance. Cancer Cell. 2025;43(6):1076-1092.e5. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.031.","journal-title":"Cancer Cell"},{"issue":"1","key":"502_CR200","doi-asserted-by":"publisher","first-page":"8923","DOI":"10.1038\/s41467-025-58992-z","volume":"16","author":"Z Zhao","year":"2025","unstructured":"Zhao Z, He J, Qiu S, Wang L, Huangfu S, Hu Y, et al. Targeting PLK1-CBX8-GPX4 axis overcomes BRAF\/EGFR inhibitor resistance in BRAFV600E colorectal cancer via ferroptosis. Nat Commun. 2025;16(1):8923. https:\/\/doi.org\/10.1038\/s41467-025-58992-z.","journal-title":"Nat Commun"},{"issue":"1","key":"502_CR201","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41392-025-02250-7","volume":"10","author":"B Liu","year":"2025","unstructured":"Liu B, Li W, Zhang W, Feng C, Wan L, He S, et al. PKMYT1 kinase ameliorates cisplatin sensitivity in osteosarcoma. Signal Transduct Target Ther. 2025;10(1):165. https:\/\/doi.org\/10.1038\/s41392-025-02250-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"502_CR202","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13046-025-03357-z","volume":"44","author":"X Liu","year":"2025","unstructured":"Liu X, Zhang S, An Y, Xu B, Yan G, Sun M. USP10\/XAB2\/ANXA2 axis promotes DNA damage repair to enhance chemoresistance to oxaliplatin in colorectal cancer. J Exp Clin Cancer Res. 2025;44(1):94. https:\/\/doi.org\/10.1186\/s13046-025-03357-z.","journal-title":"J Exp Clin Cancer Res"},{"issue":"8053","key":"502_CR203","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41586-025-09727-z","volume":"649","author":"JJ Li","year":"2025","unstructured":"Li JJ, Vasciaveo A, Karagiannis D, Sun Z, Gretarsson KH, Chen X, et al. NSD2 targeting reverses plasticity and drug resistance in prostate cancer. Nature. 2025;649(8053):216\u201326. https:\/\/doi.org\/10.1038\/s41586-025-09727-z.","journal-title":"Nature"},{"issue":"28","key":"502_CR204","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/s41388-025-03409-w","volume":"44","author":"W Wu","year":"2025","unstructured":"Wu W, Wu W, Xie X, Li J, Gao Y, Xie L, et al. DNMT1 is required for efficient DSB repair and maintenance of replication fork stability, and its loss reverses resistance to PARP inhibitors in cancer cells. Oncogene. 2025;44(28):2283\u2013302. https:\/\/doi.org\/10.1038\/s41388-025-03409-w.","journal-title":"Oncogene"},{"key":"502_CR205","doi-asserted-by":"publisher","first-page":"101100","DOI":"10.1016\/j.drup.2024.101100","volume":"76","author":"N Ji","year":"2024","unstructured":"Ji N, Li H, Zhang Y, Li Y, Wang P, Chen X, et al. Lansoprazole (LPZ) reverses multidrug resistance (MDR) in cancer through impeding ATP-binding cassette (ABC) transporter-mediated chemotherapeutic drug efflux and lysosomal sequestration. Drug Resist Updat. 2024;76:101100. https:\/\/doi.org\/10.1016\/j.drup.2024.101100.","journal-title":"Drug Resist Updat"},{"issue":"756","key":"502_CR206","doi-asserted-by":"publisher","first-page":"eadj5705","DOI":"10.1126\/scitranslmed.adj5705","volume":"16","author":"G Fan","year":"2024","unstructured":"Fan G, Yu B, Tang L, Zhu R, Chen J, Zhu Y, et al. TSPAN8 cancer\u2013associated fibroblasts promote chemoresistance in patients with breast cancer. Sci Transl Med. 2024;16(756):eadj5705. https:\/\/doi.org\/10.1126\/scitranslmed.adj5705.","journal-title":"Sci Transl Med"},{"key":"502_CR207","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.bioactmat.2025.06.010","volume":"52","author":"J Chen","year":"2025","unstructured":"Chen J, Ma F, Chen Y, Xu M, Zhang Y, Wang S, et al. Synergistic therapy for pancreatic cancer by deactivating cancer-associated fibroblasts and driving T-cell migration into tumor microenvironment using nanochaperone delivery system. Bioact Mater. 2025;52:287\u201399. https:\/\/doi.org\/10.1016\/j.bioactmat.2025.06.010.","journal-title":"Bioact Mater"},{"issue":"12","key":"502_CR208","doi-asserted-by":"publisher","first-page":"102480","DOI":"10.1016\/j.xcrm.2025.102480","volume":"6","author":"B Wang","year":"2025","unstructured":"Wang B, Li Y, Shi M, Liao Y, Ruan Y, Han S, et al. Targeting CTGF overcomes resistance to CSF1R inhibitors by preventing CAF activation in colorectal cancer. Cell Rep Med. 2025;6(12):102480. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102480.","journal-title":"Cell Rep Med"},{"issue":"8048","key":"502_CR209","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","volume":"637","author":"A Lyu","year":"2024","unstructured":"Lyu A, Fan Z, Clark M, Lea A, Luong D, Setayesh A, et al. Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature. 2024;637(8048):1207\u201317. https:\/\/doi.org\/10.1038\/s41586-024-08290-3.","journal-title":"Nature"},{"issue":"3","key":"502_CR210","doi-asserted-by":"publisher","first-page":"e012521","DOI":"10.1136\/jitc-2025-012521","volume":"13","author":"J Ma","year":"2025","unstructured":"Ma J, Mao X, Ren Y, Lin X, Wu Q, Zhang M, et al. Antagonism of estrogen-related receptor-\u03b1 inhibits mitochondrial oxidative phosphorylation and reduces M2 macrophage infiltration in endometrial cancer. J Immunother Cancer. 2025;13(3):e012521. https:\/\/doi.org\/10.1136\/jitc-2025-012521.","journal-title":"J Immunother Cancer"},{"issue":"28","key":"502_CR211","doi-asserted-by":"publisher","first-page":"e2513257","DOI":"10.1002\/advs.202513257","volume":"13","author":"X Liang","year":"2025","unstructured":"Liang X, Li Y, Cai J, Luo L, Yang P, Chen Y, et al. Fibrates Inhibit PLTP-induced M2 Macrophage Infiltration and Increase the Sensitivity of Hepatocellular Carcinoma to ICIs. Adv Sci. 2025;13(28):e2513257. https:\/\/doi.org\/10.1002\/advs.202513257.","journal-title":"Adv Sci"},{"issue":"26","key":"502_CR212","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1016\/j.cell.2025.10.030","volume":"188","author":"M von Locquenghien","year":"2025","unstructured":"von Locquenghien M, Zwicky P, Xie K, Jaitin DA, Sheban F, Yalin A, et al. Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy. Cell. 2025;188(26):7099-7117.e26. https:\/\/doi.org\/10.1016\/j.cell.2025.10.030.","journal-title":"Cell"},{"issue":"1","key":"502_CR213","doi-asserted-by":"publisher","first-page":"8923","DOI":"10.1038\/s41467-025-65945-z","volume":"16","author":"S-Y Wu","year":"2025","unstructured":"Wu S-Y, Zhu Y-Y, Sun J-L, Wang C-Y, Wang Y-L, Nie Y-Y, et al. Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation. Nat Commun. 2025;16(1):8923. https:\/\/doi.org\/10.1038\/s41467-025-65945-z.","journal-title":"Nat Commun"},{"key":"502_CR214","doi-asserted-by":"publisher","unstructured":"Theus A, Barkmann F, Wissel D, Boeva V, et al. CancerFoundation: A single-cell RNA sequencing foundation model to decipher drug resistance in cancer. bioRxiv. 2024:2024.11.01.621087. https:\/\/doi.org\/10.1101\/2024.11.01.621087.","DOI":"10.1101\/2024.11.01.621087"},{"issue":"6","key":"502_CR215","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/s43018-024-00756-7","volume":"5","author":"S Sinha","year":"2024","unstructured":"Sinha S, Vegesna R, Mukherjee S, Kammula AV, Dhruba SR, Wu W, et al. PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors. Nat Cancer. 2024;5(6):938\u201352. https:\/\/doi.org\/10.1038\/s43018-024-00756-7.","journal-title":"Nat Cancer"},{"issue":"12","key":"502_CR216","doi-asserted-by":"publisher","first-page":"101924","DOI":"10.1016\/j.xcrm.2024.101924","volume":"6","author":"H Zhang","year":"2025","unstructured":"Zhang H, Yang F, Xu Y, Zhao S, Jiang Y-Z, Shao Z-M, et al. Multimodal integration using a machine learning approach facilitates risk stratification in HR\/HER2- breast cancer. Cell Rep Med. 2025;6(12):101924. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101924.","journal-title":"Cell Rep Med"},{"issue":"1","key":"502_CR217","doi-asserted-by":"publisher","first-page":"8923","DOI":"10.1038\/s41467-024-49673-4","volume":"15","author":"C Zhong","year":"2024","unstructured":"Zhong C, Jiang W-J, Yao Y, Li Z, Li Y, Wang S, et al. CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer. Nat Commun. 2024;15(1):8923. https:\/\/doi.org\/10.1038\/s41467-024-49673-4.","journal-title":"Nat Commun"},{"issue":"1","key":"502_CR218","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1186\/s12967-025-06706-w","volume":"23","author":"Q Gu","year":"2025","unstructured":"Gu Q, Wang K, Lu T, Xiao Y, Wu Y, Zhou H, et al. Single-cell and spatial transcriptome analyses reveal MAZ(+) NPC-like clusters as key role contributing to glioma recurrence and drug resistance. J Transl Med. 2025;23(1):567. https:\/\/doi.org\/10.1186\/s12967-025-06706-w.","journal-title":"J Transl Med"},{"issue":"14","key":"502_CR219","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1182\/blood.2023022993","volume":"143","author":"JML Casan","year":"2024","unstructured":"Casan JML, Seymour JF, et al. Degraders upgraded: the rise of PROTACs in hematological malignancies. Blood. 2024;143(14):1218\u201330. https:\/\/doi.org\/10.1182\/blood.2023022993.","journal-title":"Blood"},{"issue":"1","key":"502_CR220","doi-asserted-by":"publisher","first-page":"8923","DOI":"10.1038\/s41467-023-38832-8","volume":"14","author":"PJ Tebon","year":"2023","unstructured":"Tebon PJ, Wang B, Markowitz AL, Davarifar A, Tsai BL, Krawczuk P, et al. Drug screening at single-organoid resolution via bioprinting and interferometry. Nat Commun. 2023;14(1):8923. https:\/\/doi.org\/10.1038\/s41467-023-38832-8.","journal-title":"Nat Commun"},{"issue":"1","key":"502_CR221","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41392-025-02507-1","volume":"10","author":"H Cheung","year":"2025","unstructured":"Cheung H, Chen H, Chen D, Zhou H, Liang C, Liu W, et al. YTHDF1 targets the chemotherapy response by suppressing NOTCH1-induced stemness in colorectal cancer. Signal Transduct Target Ther. 2025;10(1):409. https:\/\/doi.org\/10.1038\/s41392-025-02507-1.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"502_CR222","doi-asserted-by":"publisher","first-page":"102158","DOI":"10.1016\/j.xcrm.2025.102158","volume":"6","author":"D Zhou","year":"2025","unstructured":"Zhou D, Tang E, Wang W, Xiao Y, Huang J, Liu J, et al. Combined therapy with DR5-targeting antibody-drug conjugate and CDK inhibitors as a strategy for advanced colorectal cancer. Cell Rep Med. 2025;6(12):102158. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102158.","journal-title":"Cell Rep Med"},{"key":"502_CR223","doi-asserted-by":"publisher","first-page":"218445","DOI":"10.1016\/j.canlet.2026.218445","volume":"649","author":"M Cheng","year":"2026","unstructured":"Cheng M, Pang Y, Wang R, Chen X, Zhang C, Yang Y, et al. YTHDF3 facilitates DNA damage response by recognizing METTL3-mediated m6A modification to promote chemotherapy resistance in glioblastoma. Cancer Lett. 2026;649:218445. https:\/\/doi.org\/10.1016\/j.canlet.2026.218445.","journal-title":"Cancer Lett"},{"issue":"28","key":"502_CR224","doi-asserted-by":"publisher","first-page":"e2403936","DOI":"10.1002\/advs.202403936","volume":"12","author":"MB Uddin","year":"2024","unstructured":"Uddin MB, Wang Z, Yang C. Epitranscriptomic RNA m6A modification in cancer therapy resistance: challenges and unrealized opportunities. Adv Sci. 2024;12(28):e2403936. https:\/\/doi.org\/10.1002\/advs.202403936.","journal-title":"Adv Sci"},{"issue":"16","key":"502_CR225","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/JCO.22.02823","volume":"41","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study. J Clin Oncol. 2023;41(16):2893\u2013903. https:\/\/doi.org\/10.1200\/JCO.22.02823.","journal-title":"J Clin Oncol"},{"issue":"1","key":"502_CR226","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12943-025-02390-y","volume":"24","author":"L Shui","year":"2025","unstructured":"Shui L, Wu D, Yang K, Sun C, Li Q, Yin R. Bispecific antibodies: unleashing a new era in oncology treatment. Mol Cancer. 2025;24(1):212. https:\/\/doi.org\/10.1186\/s12943-025-02390-y.","journal-title":"Mol Cancer"},{"issue":"1","key":"502_CR227","doi-asserted-by":"publisher","first-page":"2492238","DOI":"10.1080\/19420862.2025.2492238","volume":"17","author":"R Briante","year":"2025","unstructured":"Briante R, Zhai Q, Mohanty S, Zhang P, O\u2019Connor A, Misker H, et al. Successful targeting of multidrug-resistant tumors with bispecific antibodies. MAbs. 2025;17(1):2492238. https:\/\/doi.org\/10.1080\/19420862.2025.2492238.","journal-title":"MAbs"},{"issue":"1","key":"502_CR228","doi-asserted-by":"publisher","first-page":"102688","DOI":"10.1016\/j.xcrm.2026.102688","volume":"7","author":"W Ning","year":"2026","unstructured":"Ning W, Liu H, Zeng H, Qin X, Xu L, Yang S, et al. A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. Cell Rep Med. 2026;7(1):102688. https:\/\/doi.org\/10.1016\/j.xcrm.2026.102688.","journal-title":"Cell Rep Med"},{"issue":"5","key":"502_CR229","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ccell.2026.04.010","volume":"44","author":"Y Wang","year":"2026","unstructured":"Wang Y, Chen Z, Wang W, Jiang L, Liang X, Liu Z, et al. Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer. Cancer Cell. 2026;44(5):789\u2013802. https:\/\/doi.org\/10.1016\/j.ccell.2026.04.010.","journal-title":"Cancer Cell"},{"issue":"1","key":"502_CR230","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41467-025-67502-0","volume":"17","author":"H Zhou","year":"2025","unstructured":"Zhou H, Chen H, Liu W, Liang C, Wang S, Yuan K, et al. Targeting of the m6A eraser ALKBH5 suppresses stemness and chemoresistance of colorectal cancer. Nat Commun. 2025;17(1):803. https:\/\/doi.org\/10.1038\/s41467-025-67502-0.","journal-title":"Nat Commun"},{"key":"502_CR231","doi-asserted-by":"publisher","first-page":"123730","DOI":"10.1016\/j.biomaterials.2025.123730","volume":"327","author":"Z Zheng","year":"2026","unstructured":"Zheng Z, Chen J, Kang Y, Ding Z, Jin C, Gan Z, et al. Dual-responsive nanoparticle system for enhanced blood-brain barrier crossing and glioblastoma penetration. Biomaterials. 2026;327:123730. https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123730.","journal-title":"Biomaterials"},{"key":"502_CR232","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jconrel.2024.10.004","volume":"376","author":"S Li","year":"2024","unstructured":"Li S, Li X, Wang N, Zhang C, Sang Y, Sun Y, et al. Brain targeted biomimetic siRNA nanoparticles for drug resistance glioblastoma treatment. J Control Release. 2024;376:67\u201378. https:\/\/doi.org\/10.1016\/j.jconrel.2024.10.004.","journal-title":"J Control Release"},{"key":"502_CR233","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jconrel.2023.02.009","volume":"355","author":"FM Kashkooli","year":"2023","unstructured":"Kashkooli FM, Jakhmola A, Homsby TK, Tavakkoli J, Kolios MC, et al. Ultrasound-mediated nano drug delivery for treating cancer: Fundamental physics to future directions. J Control Release. 2023;355:552\u201378. https:\/\/doi.org\/10.1016\/j.jconrel.2023.02.009.","journal-title":"J Control Release"},{"issue":"28","key":"502_CR234","doi-asserted-by":"publisher","first-page":"e2512563","DOI":"10.1002\/advs.202512563","volume":"13","author":"H Xu","year":"2025","unstructured":"Xu H, Hu D, Liu S, Yang L, Li J, Bai Y, et al. Folic acid-modified ginger-derived exosome-like nanoparticles co-delivering sunitinib suppress renal cell carcinoma via PI3K-Akt pathway inhibition, P-gp downregulation, and macrophage reprogramming. Adv Sci. 2025;13(28):e2512563. https:\/\/doi.org\/10.1002\/advs.202512563.","journal-title":"Adv Sci"},{"key":"502_CR235","doi-asserted-by":"publisher","first-page":"174971","DOI":"10.1016\/j.cej.2026.174971","volume":"534","author":"Z Song","year":"2026","unstructured":"Song Z, Zhang R-R, Yan Z-C, Wang J, Liu Y, Jiang C-Q, et al. Porous MXene nanoplatform with ultrahigh drug loading for synergistic photothermal\/photodynamic therapy and drug resistance reversal in osteosarcoma. Chem Eng J. 2026;534:174971. https:\/\/doi.org\/10.1016\/j.cej.2026.174971.","journal-title":"Chem Eng J"},{"issue":"28","key":"502_CR236","doi-asserted-by":"publisher","first-page":"e2412462","DOI":"10.1002\/smll.202412462","volume":"21","author":"SS Sahoo","year":"2025","unstructured":"Sahoo SS, Manna D, et al. Nanomaterial-Triggered Ferroptosis and Cuproptosis in Cancer Therapy. Small. 2025;21(28):e2412462. https:\/\/doi.org\/10.1002\/smll.202412462.","journal-title":"Small"},{"issue":"32","key":"502_CR237","doi-asserted-by":"publisher","first-page":"21156","DOI":"10.1021\/acsnano.4c04024","volume":"18","author":"H Lu","year":"2024","unstructured":"Lu H, Tong W, Jiang M, Liu H, Meng C, Wang K, et al. Mitochondria-targeted multifunctional nanoprodrugs by inhibiting metabolic reprogramming for combating cisplatin-resistant lung cancer. ACS Nano. 2024;18(32):21156\u201370. https:\/\/doi.org\/10.1021\/acsnano.4c04024.","journal-title":"ACS Nano"},{"issue":"17","key":"502_CR238","doi-asserted-by":"publisher","first-page":"6831","DOI":"10.7150\/thno.100036","volume":"14","author":"X Wang","year":"2024","unstructured":"Wang X, Wang L, Hao Q, Cai M, Wang X, An W, et al. Harnessing glucose metabolism with nanomedicine for cancer treatment. Theranostics. 2024;14(17):6831\u201382. https:\/\/doi.org\/10.7150\/thno.100036.","journal-title":"Theranostics"},{"issue":"1","key":"502_CR239","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12951-025-03132-4","volume":"23","author":"L-Y Zhang","year":"2025","unstructured":"Zhang L-Y, Chen X-T, Li R-T, Meng W, Huang G-Q, Chen Y-J, et al. Overcoming hypoxia-induced breast cancer drug resistance: a novel strategy using hollow gold-platinum bimetallic nanoshells. J Nanobiotechnol. 2025;23(1):345. https:\/\/doi.org\/10.1186\/s12951-025-03132-4.","journal-title":"J Nanobiotechnol"},{"key":"502_CR240","doi-asserted-by":"publisher","first-page":"114133","DOI":"10.1016\/j.jconrel.2025.114133","volume":"386","author":"B Hu","year":"2025","unstructured":"Hu B, Zhu D, Chan L, Tuohan M, Wang W, Lu Y, et al. Oral ruthenium-based PAD4 inhibitor modulates immunogenic cell death and neutrophil extracellular traps in triple-negative breast cancer. J Control Release. 2025;386:114133. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114133.","journal-title":"J Control Release"},{"key":"502_CR241","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jconrel.2024.01.050","volume":"367","author":"Z Yu","year":"2024","unstructured":"Yu Z, Huang L, Guo J. Anti-stromal nanotherapeutics for hepatocellular carcinoma. J Control Release. 2024;367:500\u201314. https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.050.","journal-title":"J Control Release"},{"key":"502_CR242","doi-asserted-by":"publisher","first-page":"101229","DOI":"10.1016\/j.drup.2025.101229","volume":"81","author":"J-R Wei","year":"2025","unstructured":"Wei J-R, Lu M-Y, Wei T-H, Fleishman JS, Yu H, Chen X-L, et al. Overcoming cancer therapy resistance: from drug innovation to therapeutics. Drug Resist Updat. 2025;81:101229. https:\/\/doi.org\/10.1016\/j.drup.2025.101229.","journal-title":"Drug Resist Updat"},{"key":"502_CR243","doi-asserted-by":"publisher","first-page":"144693","DOI":"10.1016\/j.cej.2023.144693","volume":"471","author":"K Li","year":"2023","unstructured":"Li K, Miao Y, Song K, He S, Zhang G, Waterhouse GIN, et al. Collaborative CuMn diatomic nanozyme to boost nanocatalytic\/mild photothermal\/chemo-therapy through overcoming therapeutic resistance. Chem Eng J. 2023;471:144693. https:\/\/doi.org\/10.1016\/j.cej.2023.144693.","journal-title":"Chem Eng J"},{"key":"502_CR244","doi-asserted-by":"publisher","first-page":"115183","DOI":"10.1016\/j.colsurfb.2025.115183","volume":"257","author":"L Zheng","year":"2026","unstructured":"Zheng L, Quan Y-Y, Peng X, Xu L, Zhang Q, Huang Z-S, et al. Gambogic acid and an NIR organic photothermal agent co-assembled nanoplatform to ignite immunogenic cell death\/HSP90 suppression\/ferroptosis for enhanced tumor mild-photothermal therapy. Colloids Surf B Biointerfaces. 2026;257:115183. https:\/\/doi.org\/10.1016\/j.colsurfb.2025.115183.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"3","key":"502_CR245","doi-asserted-by":"publisher","first-page":"e10670","DOI":"10.1002\/btm2.10670","volume":"9","author":"Q Shang","year":"2024","unstructured":"Shang Q, Chen Z, Li J, Guo M, Yang J, Jin Z, et al. Two-pronged reversal of chemotherapy resistance by gold nanorods induced mild photothermal effect. Bioeng Transl Med. 2024;9(3):e10670. https:\/\/doi.org\/10.1002\/btm2.10670.","journal-title":"Bioeng Transl Med"},{"key":"502_CR246","doi-asserted-by":"publisher","first-page":"101993","DOI":"10.1016\/j.mtbio.2025.101993","volume":"33","author":"Y Huang","year":"2025","unstructured":"Huang Y, Wang K, Yu M, Zhou Q, Wang J, Chen S, et al. Co-delivery paclitaxel and IR783 as nanoparticles for potentiated chemo-photothermal-immunotherapy of triple-negative breast cancer. Mater Today Bio. 2025;33:101993. https:\/\/doi.org\/10.1016\/j.mtbio.2025.101993.","journal-title":"Mater Today Bio"},{"key":"502_CR247","doi-asserted-by":"publisher","first-page":"149640","DOI":"10.1016\/j.cej.2024.149640","volume":"485","author":"M Ji","year":"2024","unstructured":"Ji M, Liu H, Liang X, Wei M, Shi D, Gou J, et al. Tumor cells are under siege from all sides: tumor cell-mimic metal-organic framework nanoparticles triggering Cuproptosis\/Ferroptosis\/Apoptosis for chemo-chemodynamic-photothermal-immunological synergistic antitumor therapy. Chem Eng J. 2024;485:149640. https:\/\/doi.org\/10.1016\/j.cej.2024.149640.","journal-title":"Chem Eng J"},{"issue":"1","key":"502_CR248","doi-asserted-by":"publisher","first-page":"8099","DOI":"10.1038\/s41467-024-52493-1","volume":"15","author":"Y-J Kim","year":"2024","unstructured":"Kim Y-J, Yun D, Lee JK, Jung C, Chung AJ, et al. Highly efficient CRISPR-mediated genome editing through microfluidic droplet cell mechanoporation. Nat Commun. 2024;15(1):8099. https:\/\/doi.org\/10.1038\/s41467-024-52493-1.","journal-title":"Nat Commun"},{"issue":"8","key":"502_CR249","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1093\/nar\/gkae245","volume":"52","author":"H Kohashi","year":"2024","unstructured":"Kohashi H, Nagata R, Tamenori Y, Amatani T, Ueda Y, Mori Y, et al. A novel transient receptor potential C3\/C6 selective activator induces the cellular uptake of antisense oligonucleotides. Nucleic Acids Res. 2024;52(8):4784\u201398. https:\/\/doi.org\/10.1093\/nar\/gkae245.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"502_CR250","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/s41565-024-01769-0","volume":"19","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Qin J, Yu D, Liu Y, Song D, Tian K, et al. Polymer-locking fusogenic liposomes for glioblastoma-targeted siRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2024;19(12):1869\u201379. https:\/\/doi.org\/10.1038\/s41565-024-01769-0.","journal-title":"Nat Nanotechnol"},{"issue":"10","key":"502_CR251","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s41587-024-02437-3","volume":"43","author":"K Chen","year":"2025","unstructured":"Chen K, Han H, Zhao S, Xu B, Yin B, Lawanprasert A, et al. Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR-Cas9 ribonucleoprotein. Nat Biotechnol. 2025;43(10):1445\u201357. https:\/\/doi.org\/10.1038\/s41587-024-02437-3.","journal-title":"Nat Biotechnol"},{"key":"502_CR252","doi-asserted-by":"publisher","first-page":"101122","DOI":"10.1016\/j.drup.2024.101122","volume":"76","author":"Y Lan","year":"2024","unstructured":"Lan Y, Li X, Liu B, Lu J, Zuo B, Wang Y, et al. Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma. Drug Resist Updat. 2024;76:101122. https:\/\/doi.org\/10.1016\/j.drup.2024.101122.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"502_CR253","doi-asserted-by":"publisher","first-page":"9119","DOI":"10.1038\/s41467-024-53569-8","volume":"15","author":"S Renzi","year":"2024","unstructured":"Renzi S, Digiacomo L, Pozzi D, Quagliarini E, Vulpis E, Giuli MV, et al. Structuring lipid nanoparticles, DNA, and protein corona into stealth bionanoarchitectures for in vivo gene delivery. Nat Commun. 2024;15(1):9119. https:\/\/doi.org\/10.1038\/s41467-024-53569-8.","journal-title":"Nat Commun"},{"issue":"1","key":"502_CR254","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s12951-022-01626-z","volume":"20","author":"P Yadav","year":"2022","unstructured":"Yadav P, Ambudkar SV, Rajendra Prasad N. Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer. J Nanobiotechnol. 2022;20(1):423. https:\/\/doi.org\/10.1186\/s12951-022-01626-z.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"502_CR255","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41467-023-44572-6","volume":"15","author":"Z Luo","year":"2024","unstructured":"Luo Z, Huang Y, Batra N, Chen Y, Huang H, Wang Y, et al. Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy. Nat Commun. 2024;15(1):255. https:\/\/doi.org\/10.1038\/s41467-023-44572-6.","journal-title":"Nat Commun"},{"issue":"28","key":"502_CR256","doi-asserted-by":"publisher","first-page":"e2510802","DOI":"10.1002\/advs.202510802","volume":"12","author":"T Fang","year":"2025","unstructured":"Fang T, Li L, Tariq Muhseen Z, Lane LA, Cai H, Butch CJ, et al. Strategic timing of gene silencing: cellular kinetics-based administration of siRNA for optimized photothermal cancer treatment. Adv Sci. 2025;12(28):e2510802. https:\/\/doi.org\/10.1002\/advs.202510802.","journal-title":"Adv Sci"},{"issue":"28","key":"502_CR257","doi-asserted-by":"publisher","first-page":"e2404231","DOI":"10.1002\/advs.202404231","volume":"12","author":"L Zhao","year":"2024","unstructured":"Zhao L, Ge J, Zhang R, Wang H, Liu X, Xu K, et al. Noninvasive immunotyping and immunotherapy monitoring of lung cancers via nuclear imaging of LAG-3 and PD-L1. Adv Sci. 2024;12(28):e2404231. https:\/\/doi.org\/10.1002\/advs.202404231.","journal-title":"Adv Sci"},{"key":"502_CR258","doi-asserted-by":"publisher","first-page":"103865","DOI":"10.1016\/j.redox.2025.103865","volume":"86","author":"L Chen","year":"2025","unstructured":"Chen L, Lin W, Le Z, Wan F, Zhang H, Geng S, et al. Carbon ion combined photon radiotherapy induces ferroptosis via NCOA4-mediated ferritinophagy in glioblastoma. Redox Biol. 2025;86:103865. https:\/\/doi.org\/10.1016\/j.redox.2025.103865.","journal-title":"Redox Biol"},{"issue":"5","key":"502_CR259","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jtho.2024.12.029","volume":"20","author":"B Besse","year":"2025","unstructured":"Besse B, Goto K, Wang Y, Lee S-H, Marmarelis ME, Ohe Y, et al. Amivantamab plus lazertinib in patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy: results from CHRYSALIS-2 cohort A. J Thorac Oncol. 2025;20(5):678\u201389. https:\/\/doi.org\/10.1016\/j.jtho.2024.12.029.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"502_CR260","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2402614","volume":"391","author":"S Lu","year":"2024","unstructured":"Lu S, Kato T, Dong X, Ahn M-J, Quang L-V, Soparattanapaisarn N, et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med. 2024;391(7):585\u201397. https:\/\/doi.org\/10.1056\/NEJMoa2402614.","journal-title":"N Engl J Med"},{"issue":"16 Suppl","key":"502_CR261","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1200\/JCO.2024.42.16_suppl.5013","volume":"42","author":"MD Linch","year":"2024","unstructured":"Linch MD, Leone G, Wong YNS, Jones RJ, Sankey P, Josephs DH, et al. Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: the NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial. J Clin Oncol. 2024;42(16 Suppl):5013. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.5013.","journal-title":"J Clin Oncol"},{"issue":"8048","key":"502_CR262","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s41586-024-08305-z","volume":"637","author":"I Melero","year":"2024","unstructured":"Melero I, Luken MdeM, Velasco G, Garralda E, Mart\u00edn-Liberal J, Joerger M, et al. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2024;637(8048):1218\u201327. https:\/\/doi.org\/10.1038\/s41586-024-08305-z.","journal-title":"Nature"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00502-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00502-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00502-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:06:27Z","timestamp":1782443187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00502-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":262,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["502"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00502-8","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}